University of Nebraska - Lincoln

DigitalCommons@University of Nebraska - Lincoln
Chemical & Biomolecular Engineering Theses,
Dissertations, & Student Research

Chemical and Biomolecular Engineering,
Department of

Summer 8-2011

Expression and Characterization of Protein Chimera with
Embedded Activated Protein C Generation
MinJeong Schneider
University of Nebraska-Lincoln, schneid92000@yahoo.com

Follow this and additional works at: https://digitalcommons.unl.edu/chemengtheses
Part of the Chemical Engineering Commons

Schneider, MinJeong, "Expression and Characterization of Protein Chimera with Embedded Activated
Protein C Generation" (2011). Chemical & Biomolecular Engineering Theses, Dissertations, & Student
Research. 9.
https://digitalcommons.unl.edu/chemengtheses/9

This Article is brought to you for free and open access by the Chemical and Biomolecular Engineering, Department of
at DigitalCommons@University of Nebraska - Lincoln. It has been accepted for inclusion in Chemical & Biomolecular
Engineering Theses, Dissertations, & Student Research by an authorized administrator of
DigitalCommons@University of Nebraska - Lincoln.

Expression and Characterization of Protein Chimera with Embedded Activated
Protein C Generation

by
MinJeong Schneider

A THESIS

Presented to the Faculty of
The Graduate College at the University of Nebraska
In Partial Fulfillment of Requirements
For the Degree of Master of Science

Major: Chemical Engineering

Under the Supervision of Professor Anuradha Subramanian

Lincoln, Nebraska

August, 2011

Expression and Characterization of Protein Chimera with Embedded Activated
Protein C Generation
MinJeong Schneider, M.S.
University of Nebraska, 2011
Advisor: Anuradha Subramanian
Increasing demand of medical implants has lead researchers to develop
biomaterial surfaces that offer improved performance and lower thrombogenecity. There
have been attempts to model biomaterial surfaces after the native endothelium as it
represents an optimal non-thrombotic surface. Typically, when biomaterials are contacted
with blood, they often invoke the activation of clotting cascades. Thus, to overcome
surface mediated thrombotic events, proteins and molecules with anticoagulant attributes
of the endothelium have been immobilized onto biomaterial surfaces. Protein C (PC)
plays a main role in blood coagulation and acts as an anticoagulant when it is converted
into activated protein C (APC). Activation of PC can be initiated only by thrombin (TR)thrombomodulin (TM) complex with a relatively slower reaction, and is enhanced 20fold when EPCR, the co-factor to PC, is also present. The objective of this thesis is to
generate a chimeric protein that includes the functional domains of both EPCR and TM in
an attempt to generate APC in-situ. The synthetic genes encoding the functional domains
of EPCR (1-193) and TM (224-462) with either a myc or flag linker along with a
histidine tag were first assembled by PCA/PCR method, sequenced and the synthetic
genes encoding the correct sequences for chimera I, chimera II, and TM2-His were
successfully expressed in yeast Pichia host X-33 strain. Expressed protein was analyzed
by Western blotting analysis, purified using Ni-chelate chromatography, and the ability
of EPCR-TM chimera to catalyze PC activation was tested in solution phase. Overall, the
expression level of chimera I, chimera II, and TM2-His was low, and mature proteins
were partially secreted into the medium, and His-tag purification yielded partially pure
products. Chimera containing EPCR and TM was noted to generate 1.8-fold higher APC
compared to standard TM at comparable concentrations.
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Introduction
Biomedical implants and devices play a significant role in maintaining and
improving human health. Further, the demand of medical implant devices, including
heart valves, vascular grafts, stents, and catheters, has been steadily increasing over past
century to save millions of patients[1-3], and a variety of synthetic polymeric materials
has been developed to be more biocompatible such as Dacron®, polytetrafluoroethylene
(PTFE), polyurethane (PU) and biodegradable materials [4]. Polymers such as Dacron®
and PTFE have been widely used for large vessels (7-9 mm) with a 45% of patency
compared to 60 to 80% patency of autologous vein grafts, however, patency of Dacron®
and PTFE is far lower in smaller diameter grafts (<6 mm), 20-25% patency with 1 mm
diameter microvessels[5]. The reason is that these biomaterials activate thrombus
formation on its lumen while the differential compliance at the anastomotic site
contributes to the formation of intimal hyperplasia (IH)[6]. Newer material, polyurethane
(PU), a radially compliant polymer, has been developed to reduce the occurrence of
intimal hyperplasia at the anastomotic site [7]. Since the porosity of biomaterials is a key
factor for the failure in small diameter grafts due to hyperplasia, it is imperative to
produce PU with porosity of 0.6 to 5.0 μm [8]. The patency rate in the pore sizes larger
than 5.0 μm was 75% and that of pore sizes smaller than 2.0 μm was 50%. This study
indicated that microvenous polyurethane-based prostheses with a luminal pore size larger
than 5.0 μm yielded a better patency rates than prostheses with a luminal pore size
smaller than 5.0 μm. Other interesting materials are biodegradable polymers such as
polylactic acid (PLA), plyglycolic acid (PGA), polyhydroxyalkanotae (PHA), and
plydioxanone (PDS)[6]. Even though these polymers possess the mechanical strength
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comparable to that of native vessel, researchers have been focusing on the control of
degradation rate to slow down absorption and allow sufficient time for arterial
regeneration for a long term patency[9]. An alternative strategy to improve synthetic and
degradable vascular grafts is the manipulation of proteins that compose native
extracellular matrix (ECM). Collagen gels and fibers from type I collagen, a major ECM
component in the blood vessel, are widely used to improve the mechanical strength of
grafts by preventing critical rupture of the vascular wall[10]. To overcome the limitation
of stiff collagen-based biopolymers, researchers have been exploring the elastic fibrin
gels [11], which can be produced from the patients’ own blood to prevent an
inflammatory reaction due to the implantation[12]. These grafts remained in the vein of
lambs for 15weeks and contained both collagen and elastin without any toxic
degradation. The mechanical properties were comparable to that of native coronary
arteries[13].
When these biomaterials are exposed to blood, they can cause numerous and
complex responses, including coagulation, complement activation, platelet adhesion and
activation leading to thrombosis, leukocyte adhesion, and red cell interactions that can
produce hemolytic damage[14]. To overcome these complications caused by
biomaterials, researchers have been focusing on resolving the early complication such as
coagulation and thrombosis since they can be prevented by controlling the initial protein
adsorption to eliminate undesirable response for example fibrinogen interaction with
platelets. One of the two major approaches for protein adsorption control is the surface
grafting with polyethylene oxide (PEO), which can keep the non-specific proteins away
from a surface by steric exclusion or by binding water or by phospholipid/phospholipid-
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like layers[15]. The other approach is the promotion of the selective and exclusive
binding of proteins, which results in attaining a desired specific biological activity [14].
For example, heparin is immobilized on the biomaterial surface to attract antithrombin III
that binds to thrombin, so that the surface can provide an anticoagulant effect [16].
Another example is using lysine to convert plaminogen or tissue plasminogen activator
(t-PA) into plasmin, a clot dissolving enzyme in the body. Therefore, maintenance of
hemocompatibility on the biomaterial surfaces has been one of the main issues in a long
term use[3, 4], and researchers have been taking direction in the development of
completely inert biomaterial surface against blood with a limited success [17, 18]. To
better understand the body response against blood contacting biomaterials, it is important
to review how the extrinsic and intrinsic pathways of blood coagulation contribute to
generation of thrombosis.
In the traditional view of blood coagulation, the initiation phase is triggered by the
extrinsic pathway, while amplification requires the intrinsic pathway[19]. At site of
vessel injury, disruption of endothelium exposes platelets to collagen in the vessel wall
and plasma factor VII/VIIa (FVII/FVIIa) to the integral membrane protein tissue factor
(TF). When TF complexes with plasma factor VIIa in the extrinsic pathway, initiation of
fibrin formation occurs. Alternatively, coagulation can be initiated through the intrinsic
pathway when factor XII is activated on a charged surface by contact activation [20].
Activation of factor XII is followed by activation of factor XI and factor IX. The
extrinsic and intrinsic pathway converges at the activation of factor X. Factor Xa
activates prothrombin to thrombin in the presence of the cofactor factor Va, and thrombin
converts fibrinogen to fibrin, forming blood clot. Thrombin is a key regulator for
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coagulation pathway and triggers anticoagulant pathway by forming a complex with
thrombomodulin. Thrombin-thrombomodulin complex converts protein C to activated
Protein C that can form a complex with protein S to inactivate activated factor Va and
activated factor VIIa. Figure 1 shows the schematic representation of blood coagulation
and anti-coagulation pathway and this study is focused on the anti-coagulation pathway.
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Damaged Surface
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Figure 1. Schematic representation of blood coagulation and anti-coagulation
pathway
To delay or reduce early clot formation on the biomaterial surface, researchers
have been attempted to produce biomaterial surfaces to provide anticoagulant activity at
the level of native endothelium [21-23]. A healthy endothelium demonstrates an
outstanding thromboresistancy due to soluble molecules (prostacyclin, nitric oxide, and
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antithrombin III) and membrane bound molecules (heparin sulphate (HS),
thrombomodulin)[3]. When a biomaterial, immobilized with prostacyclin (PGI2), was
contacted with blood, PGI2 started to fuse into blood stream to prevent the aggregation
and release of platelets [24]. It is very powerful material, but PGI2 is an expensive and
unstable product because its life time is less than 1min after hydrolysis under biological
conditions. Thus, this type of biomaterial is not practical, yet. Another molecule that
inhibits platelet activation is nitric oxide (NO). NO releasing peptide was added into the
main chain of polyurethane to improve thromboresistance [25]. Release of NO lasted for
two months to reduce platelet adhesion and smooth muscle cell growth, while NO release
stimulated endothelial cell proliferation. Inhibition of platelet adhesion is important in
the extrinsic coagulant pathway, whereas control of thrombin is essential in the common
coagulation pathway. In this sense, heparin was coated onto polymeric materials to
obtain an antithrombogenic function, which enhanced the binding of antithrombin III
(AT III) and thrombin, thus preventing blood coagulation [26]. The results showed that
the heparin release from Biomer/poly (NiPAAm)-coated surfaces significantly reduced
thrombus formation on test surfaces in contact with venous blood by neutralization of
thrombin and factor Xa. As mentioned above, thrombin is a key enzyme in coagulation
pathway and also plays an important role in anticoagulant pathway[27]. For this reason,
recombinant human thrombomodulin (TM), forming a 1:1 molar complex with thrombin,
has been immobilized on the expanded polytetrafluoroethyelen (ePTFE) by either a direct
coating or two-step binding process [28]. In this study, the two-step binding method rTM
activated protein C by 6000-fold compared to the buffer control and 50-85% more than
direct coating method because modified ePTFE surface immobilized rTM better to
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stabilize APC. This result supports that TM has an excellent anticoagulant function on
endothelium to generate activated protein C (APC) in the presence of thrombin[29]. To
emphasize the roles of TM in blood coagulation, it is necessary to review previous
studies on TM. These studies have explored the catalytic function of TM onto
membrane-mimetic polymer film that mimics the native endothelium by immobilizing
TM alone [30], a combination of TM and heparin [22] and TM, heparin and nitric oxide
(NO), which is capable of generating APC to inactivate factor Va and factor VIIIa.
Tseng et al designed a membrane-mimetic film containing TM by a photopolymerization
process to generate actively antithrombogenic surfaces. The result demonstrated that
increasing shear and TM surface concentration enhances the rate of protein C activation
per unit surface area. Tseng et al also immobilized TM and/or heparin onto the same
surface above to compare the thrombin production, which resulted in complete
elimination of steady-state thrombin responses by surface bound TM and heparin, and the
lowest thrombin generation was observed by TM-mediated activated PC than by heparinmediated activation of ATIII. Wu et al immobilized TM alone on the outer polymer
coating over the inner NO release film, and TM and heparin were immobilized on the
same NO releasing film to examine the biological activities of TM and heparin by APC
generation and anti-factor Xa assay. In this work, a decreased amount (19.8+/- 2.7%) of
platelet adhesion was observed by employing NO releasing polymeric coating compared
with polymer without NO release, while TM, anticoagulant agent, and heparin, enhancing
binding affinity for ATIII and thrombin, regulate the down-stream of coagulation cascade
. It is crucial to review the mechanism of anticoagulant pathway, which is initiated by
thrombin (TR)-thrombomodulin(TM) complex to activate protein C (PC).
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PC is a 62kDa plasma glycoprotein that a disulfide bond is holding a 42kDa
heavy chain and a 21kDa light chain together [31]. The composition of PC is a gammacarboxyglutamic acid residue (Gla)-rich domain, 2 epidermal growth factor (EGF)-like
domains, a short activation peptide, and the serine protease domain (SP) [32]. The Gla
domain of PC binds to calcium, negatively charged phospholipid membranes and
EPCR[33]. PC circulates in blood as a zymogen form of serine protease and PC
functions as an anticoagulant when it is converted to activated protein C (APC) by
thrombin bound thrombomodulin complex on the endothelial cell surface [34-36]. To
initiate the PC anticoagulant pathway, TR needs to bind TM with the high affinity
resulting in >1000-fold increase of the rate of PC activation [37]. TM is a single chain
endothelial cell surface glycoprotein with a molecular weight of 74kDa[38] functioning
as a potent anti-coagulant by converting TR from a procoagulant protease to an
anticoagulant. The mRNA of TM is about 4kb in length, while the cDNA is 1,728bp
long and encodes a protein of 575 amino acids[39]. TM consists of several domains: an
N-terminal domain followed by 6 repeated epidermal growth factor (EGF)-like domain, a
Ser/Thr-rich region containing chondroitin sulfate side chain, a transmembrane section,
and a short cytoplasmic tail[32]. The region the fourth, fifth and sixth EGF-like domains
of TM has the ability to bind thrombin and activate protein C[40]. The fourth EGF-like
domain interacts with serine protease domain of PC[32, 40] while TR binds to the fifth
and sixth EGF-like domains of TM [41]. In addition, the chondroitin sulfate of TM has
shown unique effects on its interaction of thrombin, including accelerated reaction of
thrombin with antithrombin III and enhanced blocking of procoagulant functions[40].
Soluble TM with chondroitin sulfate demonstrated 5-10-fold increase in thrombin affinity
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compare with TM lacking the chondroitin sulfate[40], however, the rate of PC activation
by TR-TM complex is relatively low affinity reaction (Kd = 0.7-1.0uM)[42]. On the
other hand, generation of APC is significantly increased with a high affinity reaction
(Kd= 30nM)[37] when TR-TM complex is co-existed with endothelial Protein C Receptor
(EPCR), a cell-specific type I transmembrane glycoprotein that has an ability to binds
both PC and APC on the cell surface and was identified by Esmon and Fukudome[43,
44]. A 43kDa soluble EPCR is identified in human plasma, circulating at a concentration
of 2.5nM[45]. The genomic DNA of EPCR is about 6kb [46] and the length of mRNA is
about 1.4kb, while the cDNA has 717 nucleotides encoding a protein of 238 amino acids
[43]. PC binding to EPCR is mediated by the vitamin K-dependent Gla domain that is
able to bind to negatively charged phospholipid surface[47]. Binding of PC to EPCR is
also Ca2+ -dependent, which helps Gla residues to position for assisting hydrogen
bonding interaction with EPCR[48]. When Gla domain of PC binds to EPCR, a
hydrophobic pockets of EPCR opens up to accommodate Phe4 of PC Gla domain[48].
The crystal structure of EPCR showed that the C-terminal of EPCR would be inserted
into the membrane, whereas APC would bind at the opposite end of EPCR and point
away from the membrane surface[48]. The Gla-domain of PC/APC interacts with
EPCR[33], and the Gla-domain of PC also interacts with TM and/or TR[49] and with the
phospholipid membrane. To integrate TR, TM, PC, and EPCR on a biomaterial surface
providing an efficient anticoagulant activity, a multiple protein immobilization technique
is required.
To immobilize multiple proteins and biomolecules, a number of methods have
been developed and used for biosensors, biodiagnostics, genomincs, proteomics,
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cytology, material science, and general chemistry [50]. However, challenges remain in
the development of methods such as providing selectivity in biomolecule binding and
positioning, preserving biological activity, and avoiding non-specific biomolecule
binding on the micro-scale to nano-scale surfaces [51]. Among these techniques, dippen nanolithography provides a flexible nanolithographic method capable of positioning
molecules on a substrate with 10 nm resolution [51, 52]. To attach proteins through the
reactive group on the substrate, covalent coupling is employed by chemical reactions;
however these chemical reactions can involve residues to affect the activity of the
proteins [53]. Thus, more site-specific technique has been applied by using monoclonal
antibodies [54]. This approach recognizes the protein of interest without affecting the
function of protein, but the size of antibodies is too large to be suitable for highresolution structured surface fabrication. Most of all these techniques is required to
shield the surface of the substrate with protein compatible layers to avoid the
denaturation of protein caused by the interaction with solid substrate because these
techniques are limited on silica chips, gold and galss-type surfaces, which cannot be used
in human body as a biomaterial [55]. From the review above, a site-specific
immobilization of multiple proteins is important to make all the proteins perform their
functions on the biomaterial surfaces providing an efficient anticoagulant activity. The
active site of TR (5.5nm diameter)[40] bound to fourth and sixth EGF-like domain of TM
is positioned about 6.5nm above the membrane[56], and the active site of APC (5.7nm
diameter)[57] bound to EPCR is located about 9.4nm above the phospholipid
membrane[58]. To catalyze the conversion of PC to APC by TR, the active site of TR
needs to be positioned between 0.7nm and 1.0nm with respect to the activation peptide
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region of PC [59, 60] In these studies, the natural anticoagulant components, EPCR and
TM, of the endothelial surface were sequentially and orderly immobilized via bi-dentate
moiety grafted onto a biomedical–grade polyurethane surface within a molecularly
relevant physical distance, less than 10nm, to support the enzymatic reaction and the rate
of PC activation from sequential immobilization was compared to that of random
immobilization. To achieve properly orientated EPCR on the PU surface, RCR-2 (mAb
against EPCR) was used to bind carboxyl terminal of EPCR to keep the PC-binding site,
NH2 terminal, away from the material surface [61]. The attachment of TM and EPCR
was controlled by the functional group at the end of the bi-dentate bridge with fast
coupling reaction to attach TM via carboxyl moiety followed by the slower reaction, the
nucleophilic reaction, to attach EPCR via oxirane moiety. The result showed that the
amount of APC generation from co-immobilization of TM and EPCR via bi-dentate
bridge is statistically higher level with P < 0.05 compared to that of random
immobilization. A smart design of these studies provided an equivalent distribution of
TM and EPCR due to the defined immobilization sites and eliminated a chemical grafting
of second protein to the first protein by conducting a fast coupling reaction followed by a
slower reaction, the nucleophilic addition through an oxirane surface group that is not
found on proteins or biomolecules to avoid creation of the protein-protein grafting.
However, this method has several limitations in immobilization of proteins: (1) It is hard
to guarantee that attachment of bidentate moiety bridge on the backbone of PU surface is
one hundred percent successful, which means one can have either carboxyl moiety or
oxirane moiety instead of having both moiety. If the distance between two single moieties
with corresponding proteins is close enough, they would activate the protein C exactly
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like a bidentate bridge with both TM and EPCR does. (2) It is hard to check the
distribution of bidentate moiety bridges on the PU surface, which means that bidentate
bridges can be populated on a small area of PU instead of spreading out evenly on the PU
surface. If one can modify the PU surface with bidentate bridge evenly, the rate of APC
generation would significantly be improved. (3) It is hard to control the distance between
two bidentate moiety bridges, which means that some of bidentate bridge might be too
close to each other or vice versa. If the distance between two bidentate bridges is too
close to each other, molecules might have a problem with serve as they should because of
their limited spatial arrangement. If the distance between two bidentate bridges is too far
from each other, it would not be enough to create a significant change in amount of APC
generation. To ensure immobilization of two major proteins on the biocompatible
surfaces within an enzymatically relevant distance without any chemical reactions, this
research proposes a production of chimera protein containing both TM and EPCR. This
chimeric protein created with EPCR and TM using a linker protein in between and six
additional His tag were attached at the end of TM sequence. It is important to review how
to design chimeric protein and the choice of the expression system.
A recombinant DNA technology with recently improved methods of DNA
chemical synthesis allows design and relatively rapid synthesis of modest-sized genes,
and chimeric/fusion protein techniques are widely used tools in biochemical research to
increase the expression of soluble proteins and to facilitate protein purification[62]. To
create chimeric/fusion proteins, parts of two or more different genes encoded for separate
proteins are connected by a peptide linker[62]. An adequate cushion distance is often
required when designing the linkers[63]. The length of the linkers varied from 2 to 18
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residues and the average length was 5.15 residues[64]. Arai et al. showed that chimeric
proteins with helical linkers were more elongated than those with flexible linkers, but
flexibility of liker did not reflect the flexibility in the inter-domain distance[65]. The
difference between flexible and helical liker represented the spatial separation of the two
domains in the chimeric proteins, and these linkers play an important role in chimeric
protein to control the distance, orientation, and relative motion of two functional domains
proteins[63, 65]. Number of studies has been reported that the number of steps and the
time required for purification was reduced when protein was fused with six or more
additional histidine residues at the end of C- or N-terminus [66, 67]. Hu et al purified
chimeric baculovirus with histidine tag using a simple immobilized metal affinity
chromatography (IMAC) with a high purity of 87%. This method is far simpler than the
conventional methods using multiple ultracentrifugation steps. Sonia et al used another
form of a single step metal chelating chromatography to purify a His-tagged chimeric Damino acid oxidase, and the purified protein showed a highly specific enzyme activity
with 82% yield. To optimize the production of recombinant protein, a variety of
expression systems has been developed and evaluated.
The development of novel protein expression systems has been a major feature
and challenge in biotechnology community [68, 69]. The choice of protein expression
system needs to be determined by the use of the product, not for the ease production,
since recombinant proteins designed for human use require specific glycosylation to
guarantee proper cellular targeting [69]. Escherichia coli and Chinese hamster ovary
(CHO) have been the most common expression systems to produce recombinant proteins
[68, 70]. Over the past three decades, E. Coli has been widely used as a cellular host for
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protein expression. However, E. coli as a prokaryotic host is not able to fold foreign
proteins properly and cannot perform other post-transitional modifications, and typically
does not secrete these proteins [71, 72]. Since E. coli cannot mimic mammalian
glycosylation to produce eukaryotic proteins, the proteins have a tendency to be
misfolded and biologically inactive [73]. Thus, E. coli has constraint in the types of
proteins that can be expressed, such as human insulin gene, which is a relatively modestsize and simple structure gene that can be incorporated into prokaryotic cells for gene
expression.
On the other hand, CHO cells as a mammalian system have been most broadly
used expression system for the production of complex human glycoproteins [74]. CHO
cells are enable to produce glycoproteins similar to human glycosylation patterns, but the
glycan structures formed from CHO cells are not truly identical to those produced in
human cells, which requires a modification to assure therapeutic use [75, 76]. There are
major disadvantages for using mammalian cells. The cost of maintenance and cell
growth in mammalian cells is expensive, the process of screening takes longer time, and
transmitting virus and prions is the issue [77].
Another useful expression system for the production of eukaryotic proteins is the
use of the methylotrophic yeast Pichia pastoris, which has become popular recently [71].
P. pastoris is a eukaryote, therefore, it provides the potential for producing soluble,
correctly folded recombinant proteins that have undergone all the post-translational
modifications required for functionality [71]. Another benefit of the P. pastoris is the use
of strong alcohol oxidase promoters that are able to drive the expression of a foreign
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gene(s) of interest, which results in large production of the target protein(s) with relative
technical ease and at a lower cost than most other eukaryotic systems[78].
In the past, a numerous chimeric proteins have been expressed in a various
expression systems mentioned above and the review of three antithrombogenic chimeric
proteins expressed in E. coli, CHO cell, and P. pastoris are followed. A chimeric protein,
rscu-PA-40kDa/Hir, combining the functional properties of a fibrin –specific
palsminogen activator with the inhibitory potential of a specific and potent thrombin
inhibitory, was obtained by fusion of the C-terminal amino acids 53-65 hirudin (Hir) to
the C-terminal of a 40-kDa fragment (Ser47—Leu411) of recombinant single-chain
urokinase-type palaminogen activator (recu-PA) via a 14 –amino acid linker sequence
[79]. The protein was produced by expression of the corresponding chimeric cDNA in E.
coli in order to use in thrombolytic therapy of myocardial infarction and purified using
silica gel column. The eluted protein was further purified by chromatography on copper
chelate and carboxymethyl-cellulose matrices. The purified rscu-PA-40kDa/Hir reduced
thrombin concentration to 50% at 95nM compared to 4.7nM of hirudin, and the catalytic
efficacies for plasmin-meditated conversion to two-chain molecules were comparable for
rscu-PA-40kDa/Hir and rscu-PA (0.63 and 0.65pM-1s-1, respectively). Thus, the intrinsic
specific thrombin inhibitory activity of hirudin was not fully expressed, but the activity
was compatible with that of hirugen, indicating that a higher concentrations of the
chimera was required for inhibit of blood coagulation in the circulation than lysis of a
fibrin clot. A chimeric protein, rscu-PA-40kDa/Hir, maintained the specific fibrinolytic
and plasminogen activating activity of rscu-PA as well as its finbrinolytic potency in
plasma. Another novel chimeric protein, tissue plaminogen activator (t-PA), was
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constructed by fusion of t-PA without the first three domains (finger domain, growth
factor domain, and kringle 1) with kringle 2 serine protease domain of t-PA via 7 amino
acid, GHRP-SYQ with high fibrin affinity [80]. Deletion of first three domains in t-PA
prolongs its half-life while addition of GHRP-SYQ to truncated t-PA compensates for
diminished fibrin affinity due to finger domain that is a responsible for fibrin affinity. A
chimeric truncated t-PA was expressed in Chinese Hamster Ovarian (CHO) cell and
purified by the one-step purification procedure using HiTrap Benzamidine FF (high sub)
column. The expression level of chimeric truncated t-PA was 566,917 IU/mg and 752
IU/ml with 86% of fibrin affinity of full length t-PA at fibrinogen concentration of
0.2mg/ml, based on amidolytic assay. The results demonstrated this novel chimeric t-PA
could be a promising approach to treat thrombotic disease because the fibrin binding
capacity of commercial form, Reteplase, was only 30% of that of full-length form [81].
The last chimeric to review is thrombin inhibitor, dipetarudin, and it is expressed in
expressed in P. pastoris using pPIC9 vector to compare the production of the same
chimera in E. coli[82]. Dipetarudin has 64 amino acids and three disulfide bonds
composed of the N-terminal head structure of dipetalogastin II and the exosite 1blocking
segment of hirudin, connected by a five glycine linker. Although, dipetarudin was
initially expressed in E. coli, but the yield of purified protein was low with 0.3mg/l [83].
The yield of dipetarudin in P.patoris was 500-fold higher than the yield obtained with the
E. coli system, 150mg/l and 0.3mg/l respectively, and kinetic studies showed that
dipetarudin isolated from P. pastoris inhibited the thrombin catalytic activity with an
apparent inhibition constant (Ki) of 399+/- 83fM[82] , which is consistent with the value
of 446+/- 85fM for the inhibitor isolated from E. coli[83]. In this report, cloning of
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dipetarudin in P. pastoris allowed a high-yield production, which can be increased more
by using fermentation technology.
Upon review of the expression systems and other chimeric proteins expressed in
the past, this study propose to synthesize APC generating chimeric proteins, chimera I
protein (EPCR-myc-TM2-His6) and chimera II protein (EPCR-flag-2MT-His6), as follow.
EPCR (1-193, binding of PC and APC) was fused to TM2 (4th-6th EGF-like domain,
binding of TR) via a linker protein, myc for chimera I and flag for chimera II, followed
by six additional histidine to simplify the purification steps. The sequence of TM2 in
chimera II protein is reversed. Figure 2 shows the native form of EPCR and TM and the
functional domains used for this study. The synthetic genes encoding functional element
of EPCR and TM is expressed in yeast, Pichia pastoris X-33 strain. This study shows the
expression, purification and biological activity characterization of chimeric protein
containing EPCR and TM.
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Figure 2. Schematic representation of TM and EPCR and functional domains used
for chimeric proteins The 5th and 6th EGF-like domain of TM are binding site for
thrombin and 4th EGF-like domain is enhancing the activation of Protein C. EPCR has Nlinked glycosylation site at 32, 49, and 121 and O-linked glycosylation site at 185 and
188.
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Materials and Methods
Oligonucleotide design of chimeric genes
To construct chimera I (EPCR-myc-TM-His6) and chimera II (EPCR-flag-TMHis6), the gene sequence of EPCR-1(residue 1-193 for chimera I and chimera II) was
obtained from GenBank accession no. L35545 and the gene sequence of mutant TM-2
(residue Asp226 to Lys466for chimera I and residue Ala224 to Cys462 for chimera II) was
obtained from GenBank accession no. BC035602. A myc epitope (EQKLISEEDL) and a
flag epitope (DYKDDDDK) were used as a linker to connect EPCR and TM for chimera
I and chimera II, respectively. His-tag was added at the end of TM-2 to aid protein
purification, and the amino sequence of TM-2 in chimera II was reversed. Xho I and Not
I restriction sites were designed in the gene sequence to help direct insertion into pPICZ α
A vector for protein expression analysis in Pichia pastoris.
Chimera I (1395 bp)

Chimera II (1416 bp)

Figure 3. Illustration of Chimera I and Chimera II genes.
Oligo design for chimera I was done with the Gene2Oligo software of Rouillard
and others (2004), and the oligo design for chimera II was prepared by internally
developed oligo design software of Louw and others (2010). The codon optimized
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oligonucleotides were purchased from Integrated DNA Technologies (Coralville, IA).
KOD Hot Start polymerase was obtained from Novagen (Madison, WI). Linker protein
myc was purchased from Invitrogen and flag was purchased from Sigma. A gel elute
extraction kit was obtained from Qiagen (CA).
The gene of TM2-His was constructed with residues from Ala224 to Cys462. The
gene of EPCR-His was constructed with residues from 1 to 193. In addition, His-tag was
added to the gene sequence for helping purification. Xho I and Not I restriction sites were
designed in the gene sequence to help direct insertion into pPICZ α A vector for protein
expression analysis in Pichia pastoris.
TM2-His (752bP)

EPCR-LL-His (612bP)

Figure 4. Illustration of EPCR-1 and TM2 chimeric genes.

Oligo design of EPCR-His was done with the Gene2Oligo software of Rouillard
and others (2004), and the oligo design for TM2-His was prepared by internally
developed oligo design software of Louw and others (2010). The codon optimized
oligonucleotides were purchased from Integrated DNA Technologies (Coralville, IA).
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KOD Hot Start polymerase was obtained from Novagen (Madison, WI). A gel elute
extraction kit was obtained from Qiagen (CA).
PCA synthesis of chimeric genes
The PCA (Stemmer et al., 1995) product of each chimera was carried out in a 25
µl volume containing 0.1 µM of each oligonucleotide, 200 µM of each dNTP, 4 mM
MgSO4, 400 µg/ml non-acetylated BSA and 0.5 units KOD Hot-Start Polymerase in 1X
manufacturer’s buffer from Novagen (Madison, WI). 25nM of each oligonucleotide was
used in the equimolar PCA reaction. PCA was performed under the following
conditions: a 30 second hot start at 92°C followed by 30 cycles of 92°C for 1 second and
56°C for 10 seconds and 72°C for 10 seconds, and a final extension at 72°C for
15seconds.
Assembly PCR and amplification of chimera
2ul of PCA product of each chimera was used as template for PCR amplification
with 0.7uM of forward primer and reverse primer. PCR amplification was conducted
under the following conditions: 30 seconds hot start at 94°C, followed by 35 cycles of
94°C of 2 seconds and 58°C for 3 seconds and 72°C for 10 seconds, and a final extension
at 72°C for 15 seconds
Vector constructions and expression of chimera genes in a Pichia pastoris
After amplification, gel-purified PCR products of chimera I and chimera II were
cloned into TOPO vector using Zero Blunt ® TOPO® PCR cloning kit from Invitrogen
(Carlsbad, CA). The DNA plasmids were transformed into chemically competent cells of
E. coli strain TOP-10 from Invitrogen. 10-50ul from each transformation was spread on a
prewarmed LB plates (1% tryptone, 0.5% yeast extract, 1% NaCl, and 1.5% agar, pH 7.0)
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containing 50ug/ml kanamycin and incubated overnight at 37°C. Ten positive clones of
transformants from chimera I and chimera II were selected and transferred into 5ml of LB
medium (1% tryptone, 0.5% yeast extract, and 1% NaCl pH 7.0) containing 50ug/ml
kanamycin to be cultured overnight at 37°C. Then, DNA plasmids from chimera I and
chimera II were isolated by using PureLink™ Quick Plasmid Miniprep kit (Invitrogen,
Carlsbad, CA) according to the manufacturer’s manual. The overnight cell culture was
centrifuged to separate the pellet from medium. The pellet was lysed and loaded to the
spin column to be eluted. Eluted DNA plasmids were sequenced at University of
Nebraska-Medical Center sequencing facility with gene specific primers. Sequence
analysis was performed using ChromasPro v1.5 software.
Primers
Sequence
M13 Reverse
5'-CAGGAAACAGCTATGAC-3'
M13 Forward
5'-GTAAAACGACGGCCAG-3'
Table 1. List of sequence primers used for subcloned chimera I and chimera II into
TOPO vector
Sequence verified clones from chimera I and chimera II were digested with Xho I
and Not I for 3hours at 37˚C and then directionally inserted into pPICZ α A vector that
was digested with the same enzymes. The plasmids were transformed into chemically
competent cells of E. coli strain TOP-10 from Invitrogen (Carlsbad, CA) according to
manufacturer’s protocol. 50-100ul of each transformants were spread on a prewarmed LB
plates (1% tryptone, 0.5% yeast extract, 0.5% NaCl, and 1.5% agar, pH 7.0 ) containing
25ug/ml Zeocin and incubated overnight at 37°C. Ten positive clones from chimera I
and chimera II were selected and transferred into 5ml of LB medium (1% tryptone, 0.5%
yeast extract, and 0.5% NaCl pH 7.0) containing 25ug/ml Zeocin to be cultured overnight
at 37°C. Then, DNA plasmids from chimera I and chimera II was isolated by using
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PureLink™ Quick Plasmid Miniprep kit from Invitrogen (Carlsbad, CA) and the isolated
DNA plasmids from positive clones were sequenced at University of Nebraska-Medical
Center sequencing facility with gene specific primers. Sequence analysis was performed
using ChromasPro v1.5 software.
primer name
sequence
Chimera II
5' Pichia
5’-GACTGGTTCCAATTGACAAGC-3’
3' Pichia
5'-GCAAATGGCATTCTGACATCC-3'
α Factor
5'-TACTATTGCCAGCATTGCTGC-3'
New F1
5´- CTCAGGTTACCTCTGGAGTTG -3´
Chimera I
5' Pichia
5’-GACTGGTTCCAATTGACAAGC-3’
3' Pichia
5'-GCAAATGGCATTCTGACATCC-3'
α Factor
5'-TACTATTGCCAGCATTGCTGC-3'
Old F1
5´- AAGTCACCTCTGGAGTTGTC -3´
Table 2. List of primers used for sequence analysis of chimera I and chimera II
gene after ligation with pPICZ α A vector
For EPCR-His and TM2-His, each PCR product was directly inserted into pPICZ
α A vector that was digested with the same enzymes. The rest of procedure was as same
as described above for chimera I and chimera II.
primer
name
sequence
TM2 -His
5' Pichia
5’-GACTGGTTCCAATTGACAAGC-3’
EPCR-His
3' Pichia
5'-GCAAATGGCATTCTGACATCC-3'
α Factor
5'-TACTATTGCCAGCATTGCTGC-3'
Table 3. List of primers used for sequence analysis of TM2-His and EPCR-His
gene after ligation with pPICZ α A vector
One of sequence verified clones from TM2-His were transferred into 5ml of LB
medium (1% tryptone, 0.5% yeast extract, and 0.5% NaCl, pH 7.0) containing 25ug/ml
Zeocin and incubated overnight at 37°C. DNA plasmids were isolated with Quigen gel
extraction kit (Valencia, CA). These isolated plasmids were linearized with Pme I and
transformed into electrocompetent cells of Pichia strain X-33 according to the
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manufacturer’s protocol from Invitrogen. The cells were pulsed in a 0.2cm Gene Pulser®
cuvette (Bio-Rad, Hercules, CA) at 2.0 kV, 300 Ω and 25 μF and 1ml of ice-cold 1M
sorbitol was immediately added. 200-300ul of transformants from TM2-His were spread
on prewarmed YSDS palate (1% of yeast extract, 2% of soy peptone, 2% dextrose, 1M
sorbitol, and 2% agar) containing 100ug/ml Zeocin and 500ug/ml Zeocin and incubated
at 30°C for 3-10 days until colonies formed.

Figure 5. Map of pPICZ α A vector from Invitrogen with cloning sites. pPICZ α A
vector contains 5’ AOX1 promoter for methanol-inducible, high level expression of the
gene interest in Pichia, α-factor secretion signal for efficient secretion of protein from
Pichia, AOX1 transcription termination region for permitting efficient 3’ mRNA
processing, Zeocin resistance gene for selection of transformants in E. Coli and Pichia
and pUC origin for replication and maintenance of the plasmid in E. Coli.
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Figure 6. Illustration of ligated Pichia vector and chimeric genes.
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Optimization of Induction Time
In order to achieve a higher expression level of recombinant proteins in P.
pastoris, the induction time of chimera I, chimera II, and TM2-His in a shake flask was
carried out. A single recombinant P. pastoris colony of chimera I, chimera II, and TM2His was selected from YSD plates (1% yeast extract, 2% soy peptone, 2% Dextrose, and
2% agar) with 100μg/ml Zeocin and inoculated into 3ml of YSD medium (1% yeast
extract, 2% soy peptone, and 2% Dextrose). The cell culture was incubated at 30˚C and
250rpm in a rotary shaker until OD600 reached to 2 -6. The overnight cell culture was
transferred into a 50ml baffled flask with 15ml of BMGY medium (1% yeast extract, 2%
soy peptone, 1% glycerol, 1.34% YNB without amino acids, 4x10-5% biotin, and 100mM
potassium phosphate, pH 6.0) with starting OD600 at 0.05 and incubated at 30˚C and
250rpm until OD600 reached to 2 -6. Cells were harvested and resuspended in a 50ml
baffled flask with 15ml of BMMY medium (1% yeast extract, 2% soy peptone, 1%
glycerol, 1.34% YNB without amino acids, 4x10-5% biotin, and 100mM potassium
phosphate, pH 6.0) containing 1% methanol. The cells were allowed to grow for 96
hours at 30˚C and 250rpm in a rotary shaker. To maintain induction level, 100%
methanol was added to a final concentration of methanol at 1% every 12 hours. 500μl of
cells were collected every 12 hours after addition of 100% methanol for western blotting
analysis. The cells were harvested at 3,000xg for 5minutes at 4˚C and the supernatant and
pellets were stored at -80˚C for western blotting.
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Figure 7. Schematic optimal induction time study of chimera in a shake flask.
Transformed Pichia strains encoding chimeric gene were first grown in 5ml YSD,
followed by 15ml of BMGY and 15ml of BMMY. Methanol was added to the cell
culture every 12hours in order to keep the induction level and protease inhibitor (PMSF)
was added after first 12hours induction. 500ul of cell culture was taken from each shake
flask at every 12hours. Supernatants were separated from pellets via centrifugation and
pellets were lysed. Supernatant and pellet were stored at -80C for western blotting
analysis.
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Large Scale Expression of Recombinant Proteins
After an optimal induction time for chimera I, chimera II, and TM2-His was
determined, Pichia strain X-33 cells encoding chimera I, chimera II, and TM2-His gene
were inoculated into a two different one liter flask. Each flask had 80ml of BMGY
medium (1% yeast extract, 2% soy peptone, 100mM potassium phosphate, pH 6.0 with
1.34% YNB, 4x10-5% biotin, and 1% glycerol, pH 6.0) and the starting OD600 was 0.05.
The cells were incubated at 30˚C and 250rpm in a rotary shaker until OD600 reached to 2 6. Cells from each flask were harvested and resuspended in a clean one liter flask with
80ml of BMMY medium (1% yeast extract, 2% soy peptone, 100mM potassium
phosphate, pH 6.0 with 1.34% YNB, 4x10-5% biotin, and 1% glycerol, pH 6.0)
containing 1% methanol. The cell culture was allowed to be incubated for an optimal
induction time corresponding to each recombinant protein. Methanol was added every 12
hours to induce expression of the recombinant genes. Pichia strain X-33 cells encoding
each recombinant gene were harvest by centrifugation at 3,000xg for 5min and the
supernatant and pellets were stored at -80˚C for SDS-PAGE and Western blotting.
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Figure 8. Schematic Expression Strategy for Chimera I and Chimera II (A) and
EPCR-1-His and TM2-His (B) Chimera I and Chimera II were subcloned into TOPO
vector using Zero Blunt ® TOPO® PCR cloning kit from Invitrogen (Carlsbad, CA) and
transformed into E. Coli. Selected clones were sequenced and cloned into pPICZ α A
vector, followed by transformation into Pichia strain X-33 cells via electroporation.
Transfomants were selected by Zeocin and sequenced. Sequence verified clones were
grown in YSD, BMGY, and BMMY. Supernatants were separated from the pellets via
centrifugation and stored at -80˚C for further analysis (A). EPCR-His and TM2-His were
directly cloned into pPICZ α A vector followed by transformation into Pichia strain X-33
cells via electroporation. Transfomants were selected by Zeocin and sequenced.
Sequence verified clones were grown in YSD, BMGY, and BMMY. Supernatants were
separated from the pellets via centrifugation and stored at -80˚C for further analysis (B).
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Protein extraction and purification
For secreted proteins, the supernatants were removed from growth medium by
centrifugation at 3,000xg for 5 min. Total volume of supernatant from chimera I, chimera
II, and TM2-His was 160 ml each. Supernatant was dialyzed against five liters of dialysis
buffer (10mM PBS, pH 7.0) for four hours, followed by eight hours dialysis against fresh
five liters of dialysis buffer and another four hours dialysis against fresh five liters of
fresh dialysis buffer at 4˚C. Dialyzed supernatant was concentrated down to 20 ml via
lyophilization. Concentrated supernatant was resuspended with 20 ml of 3X binding
buffer, followed by 10 ml of 1X binding buffer. The resuspended mixture was purified
with Novagen His-Bind Resin (EMD Chemicals Inc., San Diego, CA) according to the
manufacturer’s manual. Purified proteins were analyzed by SDS-PAGE and Western
blotting.
For proteins that were expressed inside the cell, pellets from each recombinant
protein were lysed to extract proteins. Total mass of pellets for chimera I, chimera II, and
TM2-His was 10 grams each. The pellets were resuspended with 16ml of lysis buffer
(50mM Tris-HCl, 10mM MgSO4, 1mM EDTA, 10mM Potassium acetate, 1mM
Dithiothreitol, and 2mM Phenylmethanesulphonyfluoride in methanol, pH 9.5). 16 ml of
ice-cold glass beads (Biospec, Bartlesville, OK) were added and vortexed for 20 seconds,
followed by 20 seconds of resting on the ice. The process was repeated 15 times. 54ml of
1X binding buffer was added to the proteins extracted from pellets and the mixture was
purified according to the Novagen His Bind Resin manual (EMD Chemicals Inc., San
Diego, CA).
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Figure 9. Schematic purification strategy of chimeric proteins. Supernatant from a
large scale (2X 80mL) expression of chimeric protein was separated from pellet via
centrifugation and the pellets were lysed. Total 160ml of supernatant from each chimera
was dialyzed against 10mM PBS pH 7.5 and the total volume was 200ml, followed by
lyophilization to bring the volume down to 20ml. 54ml of 1X binding buffer was added
to lyophilized supernatant and purified with Novagen His-Bind resin (EMD Chemicals
Inc., San Diego, CA) in a batch mode. Eluted proteins were diafiltered with Sartorius
stedium biotech Vivaspin 4 from Fisher Scientific (Pittsburgh, PA) to be concentrated. A
soluble lysate from pellets was mixed with 20ml of 3X binding buffer and 10ml of 1X
binding buffer, and purified with Novagen His-Bind resin from EMD (Gibbstwon, NJ) in
a batch mode. Eluted proteins were diafiltered with Sartorius stedium biotech Vivaspin 4
(Fisher Scientific, Pittsburgh, PA) to be concentrated.
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Western blotting
For Western blotting, 10 ml of supernatant of chimera I, TM2-His, and EPCR-His
was concentrated to 2 ml via lyophilization. 4ml of chimera II was diafiltered against
10mM PBS, pH 7.5 and concentrated to 200 μl via lyophilization. Protein samples
obtained from supernatant were prepared under reducing condition. 10 μl of LDS buffer
(Invitrogen, Carlsbad, CA), 4 μl of reducing agent (Invitrogen, Carlsbad, CA), and 16 μl
of water were added to 10 μl of chimera I, TM2-His, and EPCR-His and 30 μl of chimera
II from processed supernatant above. Protein samples obtained from pellet lysate were
prepared under reducing condition. 2.5 μl of 4X LDS buffer (Invitrogen, Carlsbad, CA),
1 μl of reducing agent (Invitrogen, Carlsbad, CA), and 1.5 μl of water were added to 5 μl
of chimera I, chimera II, TM2-His, and EPCR-His. These prepared samples were heated
at 100˚C for 10 minutes, cooled down on the ice, centrifuged for 1 min at 13,000 rpm,
and loaded on 4-12% Bis-Tris NuPAGE gels (Invitrogen, Carlsbad, CA). The proteins
were separated by gel electrophoresis with NuPAGE MOPS SDS Running Buffer at 200
V for 50 minutes. Proteins were electroblotted onto a PVDF membrane (Millipore,
Billerica, MA) by applying 23 volts for 35 minutes and then probed with a mouse
monoclonal antibody against histidine (1:100), a rabbit polyclonal antibody against
EPCR (1:1000), a mouse monoclonal antibody against human thrombomodulin (1:1000),
a mouse monoclonal antibody against myc (1:5000) and a mouse monoclonal antibody
against flag (1:1000). The signals were visualized with Pierce ECL Western blotting
substrate (Fisher Scientific, Pittsburgh, PA) and hyperfilm ECL (Amersham Biosciences,
Piscataway, NJ).
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For partially pure proteins, the protein samples were prepared under reducing
condition. 10ul of LDS buffer (Invitrogen, Carlsbad, CA) and 4ul of reducing agent
(Invitrogen, Carlsbad, CA) was added to partially pure protein from pellet lysate of
chimera I (7ul), TM2-His (10ul), and chimera II (10ul). The rest of sample volume was
filled up with water to make a total volume of 40 μl. 10ul of LDS buffer (Invitrogen,
Carlsbad, CA) and 4ul of reducing agent (Invitrogen, Carlsbad, CA) was added to
partially pure protein from supernatant TM2-His (1.5ul), chimera I (2ul), and EPCR-His
(2ul). The rest of sample volume was filled up with water to make a total volume of 40
μl. These samples were heated at 100˚C for 10 minutes, cooled down on the ice,
centrifuged for 1min at 13,000 rpm, and loaded on 4-12% Bis-Tris NuPAGE gels
(Invitrogen, Carlsbad, CA). The proteins were separated by gel electrophoresis with
NuPAGE MOPS SDS Running Buffer at 200 V for 50 minutes. Proteins were
electroblotted onto a PVDF membrane (Millipore, Billerica, MA) by applying 23 volts
for 35 minutes and then probed with a mouse monoclonal antibody against histidine
(1:100). The signals were visualized with Pierce ECL Western blotting substrate (Fisher
Scientific, Pittsburgh, PA) and hyperfilm ECL (Amersham Biosciences, Piscataway, NJ)

Binding ability of partially pure proteins with human Protein C and human α
thrombin
To check the binding ability of partially pure proteins with human protein C (hPC,
Enzyme Research Labs, South Bend, IN) and human α thrombin (Enzyme Research
Labs, South Bend, IN), the protein samples were prepared under reducing condition in
the same manner explained above. Electroblotted proteins on a PVDF membrane was
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incubated with 2 μg/ml human protein C and 2 μg /ml thrombin. The signals were
visualized with Pierce ECL Western blotting substrate (Fisher Scientific, Pittsburgh, PA)
and hyperfilm ECL (Amersham Biosciences, Piscataway, NJ).
Primary antibody
Host
Animal

Manufacturer

Cat #

Vendor
EMD
bioscience

Dilution

anti-His
Mouse
Calbiochem 13/45/31/2
(1:100)
antiEPCR
Rabbit
Zymed
40-2900
Invitrogen
(1:1000)
anti-TM
Mouse
abcam
6980
abcam
(1:1000)
anti-myc
Mouse
Invitrogen
R950-25
Invitrogen
(1:5000)
anti-flag
Mouse
Sigma
F1804
Sigma
(1:1000)
Table 4. List of primary antibodies used for detection of proteins expressed in
Pichia strain of X-33 cell.

Secondary antibody
Manufacturer
Cat #
Vendor Dilution
anti-His
anti-Mouse
KPL
074-1806
KPL
(1:2000)
anti-EPCR
anti-rabbit
KPL
074-1506
KPL
(1:1000)
anti-TM
anti-Mouse
KPL
074-1806
KPL
(1:1000)
anti-myc
anti-Mouse
KPL
074-1806
KPL
(1:1000)
anti-flag
anti-Mouse
KPL
074-1806
KPL
(1:5000)
Table 5. List of secondary antibodies used for detection of proteins expressed in
Pichia strain of X-33 cell.

Protein
MW (kDa)
Cat #
Manufacturer
Human Protein C
62
HPC1001 Enzyme Research lab
human α thrombin
37
HT1002a Enzyme Research lab
Table 6. List of proteins used in binding ability of proteins expressed in Pichia
strain of X-33 cell with human protein C and human α thrombin.
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Antibody

Cat #
Manufacturer
Dilution
SHPCHRP-conjugated anti-human protein C
180
Enzyme Research lab (1:1000)
HRP-conjugated anti-human α
SHATthrombin
140
Enzyme Research lab (1:1000)
Table 7. List of HRP conjugated antibodies used in binding ability of proteins
expressed in Pichia strain of X-33 cell with human protein C and human α
thrombin.

SDS-PAGE
Proteins that were partially purified from supernatant and pellet lysate were
analyzed by SDS-PAGE gel electrophoresis on a 4-12% Bis-Tris NuPAGE gels
(Invitrogen, Carlsbad, CA) under reducing condition. For partially purified protein from
pellet lysate, 10 μl of LDS buffer (Invitrogen, Carlsbad, CA) and 4 μl of reducing agent
(Invitrogen, Carlsbad, CA) were added to chimera I (7ul), TM2-His (10ul), and chimera
II (10ul). The rest of sample volume was filled up with water to make a total volume of
40 μl. For partially purified protein from supernatant, 10ul of LDS buffer (Invitrogen,
Carlsbad, CA) and 4ul of reducing agent (Invitrogen, Carlsbad, CA) were added to TM2His (1.5ul), chimera I (2ul), and EPCR-His (2ul). The rest of sample volume was filled
up with water to make a total volume of 40 μl. These samples were heated at 100˚C for
10 minutes, cooled down on the ice, centrifuged for 1 minute at 13,000 rpm, and loaded
on 4-12% Bis-Tris NuPAGE gels (Invitrogen, Carlsbad, CA). The gel was run at 200 V
for 50 minutes. Proteins were visualized by staining with Silver Quest™ Silver Staining
Kit (Invitrogen, Carlsbad, CA) according to the manufacturer's protocol. After gel
electrophoresis, the gel was fixed in fixative solution for overnight, followed by
incubation in staining solution for 15 minutes and in developing solution until the bands
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were visualized in the gel. Once the desired band intensity was achieved 10 ml of stopper
solution was added to the gel.
Solution Phase Protein C Activation Assay
The ability of partially pure chimera I and TM2-His to catalyze the activation of
protein C was assayed in the solution phase. Protein solutions ofTM2-His, chimera I,
human α thrombin (TR, Enzyme Research Labs, South Bend, IN), human Protein C
(hPC, Enzyme Research Labs, South Bend, IN), and human activated Protein C (aPC,
Enzyme Research Labs, South Bend, IN), were prepared in reaction buffer (0.1 M NaCl,
0.003 M CaCl2, 0.0006 M MgCl2, 0.02 M Tris-HCl, 0.1 mg/ml Bovine Serum Albumin,
pH 7.5). For chimera I, 25 μl of reaction buffer, 25 μl of a 0.05 mg/ml hPC solution, and
a various concentration of partially pure chimera I from supernatant and pellet lysate
were incubated for 15 minutes at room temperature in a sterile 96 well cell culture plate
(Fisher Scientific, Pittsburgh, PA). At the same time, 25μl of reaction buffer and 25μl of
a 0.05 mg/ml hPC solution were incubated for 15 minutes at room temperature in the
same cell culture plate, followed by addition of 25 μl of various concentration of partially
pure TM2-His from supernatant and pellet lysate. Finally, 25 μl 0.03 μg/ml TR was
added to the reaction mixture of chimera I and TMs-His, which was incubated at 37˚C for
30 minutes. For the standard curve of activated Protein C, 100 μl of various
concentration of human activated Protein C was added to the same 96 well cell culture
plate. To measure the amount of activated PC from each well, 25 μl of spectrozyme aPC
(American Diagnostica Inc., Stamford, CT) was added to a final concentration of
0.0004M. The reaction was incubated at 37˚C and the absorbance was taken after 0, 30

36

and 60 minutes at 405 nm using a Beckman Coulter AD 340 UV/Vis microplate reader.
The concentration of generated APC was calculated using an APC in reaction buffer
calibration curve on the same cell culture plate.
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Results
Vector construction and expression of chimeric genes in a Pichia pastoris
Upon the completion of subcloning chimera I and chimera II into TOPO vector,
ten clones each from experiment were selected and were further sequenced to ascertain
the DNA sequence of the desired insert comparing the reference sequence of insert. The
clones that are determined to possess the correct sequence (sequences are listed in the
Appendix) listed in Table 8.
After sequence verification, clone #1 from chimera I and clone #2 from chimera II
were selected to further insertion into pPICZ α A vector. The PCR product of TM2-His
was directly inserted into a pPICZ α A vector. Table 9 shows that five clones from
chimera I, eight clones from chimera II, and six clones from TM2-His are in frame with
pPICZ α A vector. Error free Clone #1-6 from chimera I, #2-4 from chimera II, and #1
from TM2-His were selected for expression in Pichia host X-33 strain.
Optimization of Induction Time
Clones were first expressed in small scale cultures (~15 ml) and Western blotting
was performed to aid in the selection of viable clones for further growth and optimization
in a large scale expression (~80 ml). Typically, all clones were grown up to 96 hours and
samples were taken at 24, 48 and 96 hours. Figure 10 shows the result of Western blot
analysis on the samples obtained at 24 hour induction time from small scale culture.
Panel-A shows the supernatants obtained from transformed Pichia cells carrying the gene
for chimera-I. Based on observed band intensities, clones R2, R6 and R7 were chosen for
further western blot analysis. Panel-B shows the supernatants obtained from transformed
Pichia cells carrying the gene for chimera-II. Based on observed band intensities, clones
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O3 and R2 were chosen for further western blot analysis. Panel-C shows the supernatants
obtained from transformed Pichia cells carrying the gene for TM2-His. Based on
observed band intensities, clones O1, O4, and R2 were chosen for further western blot
analysis.
In the next step, samples obtained at 24, 48, and 96 hour from selected clones
were also analyzed by western blot analysis (Figure 11/12/13). With increasing induction
time, all selected clones show higher levels of expression. Clone z100 R2 from chimera I,
z100 R2 from chimera II, and z100 O1 from TM2-His show stronger signal, implying
higher expression. Based on the band intensity, Pichia cells carrying the gene for chimera
I was grown up to 48 hours, Pichia cells carrying the gene for chimera II was grown up
to 96 hours , and Pichia cells carrying the gene for TM2-His was grown up to 96 hours in
a large scale culture.
Large Scale Expression of Recombinant Proteins
The samples obtained at 24, 48, and 96 hours of supernatant and pellet lysate from
a large scale culture were analyzed by Western blotting analysis to confirm the
expression levels of selected clones. Figure 14 shows clone #1-6 z100 R2 carrying
genetic elements encoding chimera I in Pichia strain of X-33 cell. Figure 15 shows clone
#2-4 z100 R2 carrying genetic elements encoding Chimera II in Pichia strain of X-33
cell. Figure 16 shows clone #1 z100 O1 carrying genetic elements encoding TM2-His in
Pichia strain of X-33 cell. With increasing induction time, all selected clones show
higher levels of expression. In the next step, supernatant and pellet lysate of chimera I at
48 hour, chimera II at 96 hour, and TM2-His at 96 hour were subjected to further
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Western blot analysis to confirm whether each chimeric protein preserves all genetic
elements.
Detection of expressed chimera I, chimera II, and TM2-His protein
Proteins obtained from supernatant and pellet lysate of chimera I, chimera II, and
TM2-His were detected by western blot analysis with various antibodies. First, reduced
Western blots probed with a mouse monoclonal antibody against histidine are shown in
Figure 17. Panel-A shows the proteins obtained from the supernatant of TM2-His (lane
1), EPCR-His (lane 2), chimera I (lane 3), and chimera II (lane 4). The expected
molecular weight of TM2-His was 42 kDa and the protein was detected at 42 kDa. The
expected molecular weight of EPCR-His was 38 kDa and the protein was detected at 38
kDa. The expected molecular weight of chimera I was 78 kDa and the protein was
detected at 78 kDa with a light protein band around 40 kDa. The expected molecular
weight of chimera II was 78 kDa and the protein was detected at 78 kDa with a light
protein band around 40 kDa. Panel-B shows the proteins obtained from the pellet lysate
of TM2-His (lane 1), chimera I (lane 2), and chimera II (lane 3). All proteins from the
pellet lysate show multiple bands with a band at their expected molecular weight.
Second, reduced Western blots probed with a rabbit polyclonal antibody against
EPCR are shown in Figure 18. Panel-I shows the proteins obtained from the supernatant
of EPCR-His (lane 1), chimera I (lane 2), and chimera II (lane 3). The expected
molecular weight of EPCR-His was 38 kDa and the protein was detected as expected.
The expected molecular weight of chimera I was 78 kDa and the protein was detected at
78 kDa with a light protein band around 40 kDa. The expected molecular weight of
chimera II was 78 kDa and the protein was detected at 78 kDa with a light protein band
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around 40 kDa. Panel-II shows the proteins obtained from the pellet lysate of TM2-His
(lane 1), chimera I (lane 2), and chimera II (lane 3). All proteins from the pellet lysate
show multiple bands, and chimera II has a strong signal at 78 kDa.
Third, reduced Western blots probed with a mouse monoclonal antibody against
thrombomodulin are shown in Figure 19. Panel-I shows the proteins obtained from the
supernatant of TM2-His (lane 1), EPCR-His (lane 2), chimera I (lane 3), and chimera II
(lane 4). The expected molecular weight of TM2-His was 42 kDa and the protein was
detected as expected. EPCR-His was not detected. The expected molecular weight of
chimera I was 78 kDa and the protein was detected at 78 kDa with a light protein band
around 40 kDa. The expected molecular weight of chimera II was 78 kDa and the protein
was detected at 78 kDa with a light protein band around 40 kDa. Panel-II shows the
proteins obtained from pellet lysate of TM2-His (lane 1), chimera I (lane 2), and chimera
II (lane 3). All proteins from the pellet lysate show multiple bands with a band at the
expected molecular weight.
Fourth, reduced Western blots probed with a mouse monoclonal antibody against
myc are shown in Figure 20. Panel-I shows the proteins obtained from the supernatant of
TM2-His (lane 1), EPCR-His (lane 2), and chimera I (lane 3). TM2-His and EPCR-His
was not detected. The expected molecular weight of chimera I was 78 kDa and the
protein was detected at 78 kDa with a light protein band around 40 kDa. Panel-II shows
the proteins obtained from the pellet lysate of TM2-His (lane 1), chimera I (lane 2), and
chimera II (lane 3). TM2-His and chimera II were not detected on the blot. The expected
molecular weight of chimera I was 78 kDa and the protein was detected at 78 kDa with
other multiple bands.
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Fifth, reduced Western blots probed with a mouse monoclonal antibody against
flag are shown in Figure 21. Panel-I shows the proteins obtained from the supernatant of
TM2-His (lane 1), EPCR-His (lane 2), chimera I (lane 3), and chimera II (lane 4). The
expected molecular weight of chimera II was 78 kDa and the protein was detected at 78
kDa with a strong protein band around 40 kDa and other bands. TM2-His, EPCR-His,
and chimera I were not detected on the blot. Panel-II shows the proteins obtained from
the pellet lysate of TM2-His (lane 1), chimera I (lane 2), and chimera II (lane 3). All
proteins from the pellet lysate show multiple bands. The results of Western blot analysis
to detect the functional elements and the linkers of chimeric proteins are summarized in
Table 10.
Western blot analysis of proteins obtained from His-resin purification
Proteins of chimera I, chimera II, TM2-His and EPCR-His obtained from Hisresin purification were analyzed to check the purity of these proteins by Western blot
with an antibody against histidine. The expected molecular weight of chimera I, chimera
II, TM2-His, EPCR-His was 78, 78, 42, and 38 kDa, respectively. Figure 22 shows
proteins from the pellet lysate of TM2-His (lane 1), chimera II (lane 2), and chimera I
(lane 3) and proteins from the supernatant of EPCR-His (lane 4), TM2-His (lane 5),
chimera II (lane 6), chimera I (lane 7), and EPCR-His (lane 8). Most of proteins were
detected at their corresponding molecular weight along with multiple bands. Protein from
the supernatant of chimera II (lane 6) was not detected at all and protein from the
supernatant of EPCR-His (lane 8) was barely detected with a faint signal.
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Silver staining analysis of proteins obtained from His-resin purification
Proteins of chimer I, chimera II, TM2-His and EPCR-His obtained from His-resin
purification were analyzed to check the purity of these proteins were analyzed by SDSPAGE and silver staining (Figure 23). The expected molecular weight of chimera I,
chimera II, TM2-His, EPCR-His was 78, 78, 42, 38 kDa, respectively. Proteins from the
pellet lysate of chimera I (lane 1), chimera II (lane 2), and TM2-His (lane 3) have
multiple bands. All of purified proteins have a band at 62 kDa. Proteins from the
supernatant of TM2-His (lane 5), chimera I (lane 7), and EPCR-His (lane 9), and have
multiple bands. TM2-His (lane 5) has one band at 42 kDa with other multiple bands.
Chimera I (lane 7) has one band at 45 kDa and the other band at 62 kDa. EPCR-His (lane
4), chimera I (lane 6), and EPCR-His (lane 8) have only one band at 62 kDa.
Binding ability of partially pure proteins with human Protein C and human α
thrombin
Figure 24 shows that partially pure proteins of chimera I, chimera II, TM2-His,
and EPCR-His, were electroblotted, incubated with human protein C, and detected with a
HRP-conjugated anti-human protein C. All of proteins are bound to human protein C,
except for protein from the supernatant of chimera II (lane 6). Figure 25 shows that
partially pure proteins of chimera I, chimera II, TM2-His, and EPCR-His, were
electroblotted, incubated with human α thrombin, and detected with a HRP-conjugated
anti-human α thrombin. All of proteins are bound to human α thrombin, except for
protein from the supernatant of chimera II (lane 6) and EPCR-His (lane 8).
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Solution Phase Protein C Activation Assay
The ability of partially pure chimera I and TM2-His to catalyze the activation of
Protein C was assayed in the solution phase. We used the APC values obtained from
4762, 2381, 595, and 297 nM of TM2-His (supernatant) in the experiment to extrapolate
the APC value of 961 nM of TM2-His (supernatant). To extrapolate the APC values of
320 nM and 160 nM of TM2-His (pellet), we used the APC values obtained from 595 and
297 nM of TM2-His (pellet) in the experiment. The final APC values presented in this
study were averaged from 30 minute and 60 minute reading at 405 nm after the activation
of Protein C.
Figure 26 shows the amount of APC generated from partially pure proteins of
chimera I and TM2-His. Chimera I (supernatant) at 961 nM produced 0.979 nM of APC,
chimera I (pellet) at 320 nM produced 3.768 nM of APC, and chimera I (pellet) at 160
nM produced 1.370 nM of APC. TM2-His (supernatant) at 961 nM produced 0.540 nM
of APC, TM2-His (pellet) at 320 nM produced 2.048 nM of APC, and TM2-His (pellet)
at 160 nM produced 0.676 nM of APC. Human Protein C alone, thrombin alone, or
human Protein C and thrombomodulin together did not produced activated Protein C. The
control sample produced 9.1 nM of APC with commercial proteins of hPC, rabbit Lung
TM, and thrombin in the absence of EPCR.
Overall the activity level of chimera I is twice higher than that of TM2-His at the
same concentration of proteins from both supernatant and pellet lysate, and the activity
level of protein from the pellet lysate is higher than that of proteins from the supernatant.
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(A) Chimera I, Supernatant,24hr (B) Chimera II, Supernatant,24hr (C) TM2-His, Supernatant,24 hr

Figure 10. Western blotting analysis of small scale induction experiments probed
with anti-His. Selected clones of Pichia cells carrying the gene for chimera I, chimera II,
and TM2-His were first grown in BMGY, followed by BMMY and fractions were
analyzed at 24 hours induction in cell culture. Supernatants were separated from via
centrifugation and pellets were lysed. Supernatants were analyzed by western blotting
and probed with a mouse monoclonal antibody against. (Z100: Zeocin 100 µg/ml, z 500:
Zeocin 500 µg/ml, O: original plate, R: restreaked plate)

(A) Chimera I, Supernatant

(B) Chimera I, Pellet lysate

Figure 11. Western blotting analysis of small scale induction experiment probed
with anti-His. Pichia cells carrying the gene for chimera I (clone #1-6) were first grown
in BMGY, followed by BMMY and fractions were analyzed at 24, 48, and 96 hours upon
induction in cell culture. Supernatants were separated from via centrifugation and pellets
were lysed. 10 µl of supernatant and 5 µl of soluble lysate from pellet were analyzed by
Western blotting and probed with a mouse monoclonal antibody against histidine. (Z100:
Zeocin 100 µg/ml, R: restreaked plate)
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(A) Chimera II, Supernatant
(B) Chimera II, Pellet lysate
Figure 12. Western blotting analysis of small scale induction experiment probed
with anti-His. Pichia cells carrying the gene for chimera II (clone #2-4) were first grown
in BMGY, followed by BMMY and fractions were analyzed at 24, 48, and 96 hours upon
induction in cell culture. Supernatants were separated from via centrifugation and pellets
were lysed. 30 µl of supernatant and 5 µl of soluble lysate from pellet were analyzed by
Western blotting and probed with a mouse monoclonal antibody against histidine. (Z100:
Zeocin 100 µg/ml, O: original plate, R: restreaked plate).

(A) TM2-His, Supernatant
(B) TM2-His, Pellet lysate
Figure 13. Western blotting analysis of small scale induction experiment probed
with anti-His. Pichia cells carrying the gene for TM2-His (clone #1) were first grown in
BMGY, followed by BMMY and fractions were analyzed at 24, 48, and 96 hours upon
induction in cell culture. Supernatants were separated from via centrifugation and pellets
were lysed. 10 µl of supernatant and 5µl of soluble lysate from pellet were analyzed by
Western blotting and probed with a mouse monoclonal antibody against histidine. (Z100:
Zeocin 100 µg/ml, O: original plate, R: restreaked plate).
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(A) Chimera I, Supernatant
(B) Chimera I, Pellet lysate
Figure 14. Western blotting analysis of large scale induction experiment probed
with anti-His. Pichia cells carrying the gene for chimera I (clone #1-6z100 R2) were
first grown in BMGY, followed by BMMY and fractions were analyzed at 24 and 48
hours upon induction in cell culture. Supernatants were separated from via centrifugation
and pellets were lysed. 10 µl of supernatant and 5 µl of soluble lysate from pellet were
analyzed by Western blotting and probed with a mouse monoclonal antibody against
histidine.

(A) Chimera II, Supernatant
(B) Chimera II, Pellet lysate
Figure 15. Western blotting analysis of large scale induction experiment probed
with anti-His. Pichia cells carrying the gene for chimera II (clone #2-4 z100 R2) were
first grown in BMGY, followed by BMMY and fractions were analyzed at 24 and 48
hours upon induction in cell culture. Supernatants were separated from via centrifugation
and pellets were lysed. 30 µl of supernatant and 5 µl of soluble lysate from pellet were
analyzed by Western blotting and probed with a mouse monoclonal antibody against
histidine.
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(A) TM2-His, Supernatant
(B) TM2-His, Pellet lysate
Figure 16. Western blotting analysis of large scale induction experiment probed
with anti-His. Pichia cells carrying the gene for TM2-His (clone #1 z100 O1) were first
grown in BMGY, followed by BMMY and fractions were analyzed at 24, 48, and 96
hours upon induction in cell culture. Supernatants were separated from via centrifugation
and pellets were lysed. 10 µl of supernatant and 5ul of soluble lysate from pellet were
analyzed by Western blotting and probed with a mouse monoclonal antibody against
histidine.
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(A) Supernatant before purification

(B) Pellet lysate before purification

Figure 17. Western blotting analysis of proteins expressed in Pichia Pastoris probed
with anti-His. Transformed Pichia strains were first grown in BMGY, followed by
BMMY. Supernatants were separated from via centrifugation and pellets were lysed.
Supernatant and soluble lysate from pellet were analyzed by western blotting and probed
with a mouse monoclonal antibody against histidine. (I) P: positive control (Positope),
lane 1: TM2-His (5X concentrated), lane 2: EPCR-His (5X concentrated), lane 3:
Chimera I (5X concentrated), lane 4: Chimera II (20X concentrated) (II) P: positive
control (Positope), lane 1: TM2-His, lane 2: Chimera I, lane 3: Chimera II
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(A) Supernatant before purification

(B) Pellet lysate before purification

Figure 18. Western blotting analysis of chimeric proteins expressed in Pichia
Pastoris probed with anti-EPCR. Transformed Pichia strains were first grown in
BMGY, followed by BMMY. Supernatants were separated from via centrifugation and
pellets were lysed. Supernatant and soluble lysate from pellet were analyzed by western
blotting and probed with a rabbit polyclonal antibody against EPCR. (I) P: positive
control (143.5ng of EPCR-LL), lane 1: EPCR-His (5X concentrated), lane 2: Chimera I
(5X concentrated), lane 3: Chimera II (20X concentrated) (II) P: positive control
(143.5ng of EPCR-LL), lane 1: TM2-His, lane 2: Chimera I, lane 3: Chimera II
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(A) Supernatant before purification

(B) Pellet lysate before purification

Figure 19. Western blotting analysis of chimeric proteins expressed in Pichia
Pastoris probed with anti-TM. Transformed Pichia strains were first grown in BMGY,
followed by BMMY. Supernatants were separated from via centrifugation and pellets
were lysed. Supernatant and soluble lysate from pellet were analyzed by western blotting
and probed with a mouse monoclonal antibody against thrombomodulin. (I) P: positive
control (50ng of human Thrombomodulin), lane 1: TM2-His (5X concentrated), lane 2:
EPCR-His (5X concentrated), lane 3: Chimera I (5X concentrated), lane 4: Chimera
II_20X concentrated (II) P: positive control (100ng of human Thrombomodulin), lane 1:
TM2-His, lane 2: Chimera I, lane 3: Chimera II
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(A) Supernatant before purification

(B) Pellet lysate before purification

Figure 20. Western blotting analysis of chimeric proteins expressed in Pichia
Pastoris probed with anti-myc. Transformed Pichia strains were first grown in BMGY,
followed by BMMY. Supernatants were separated from via centrifugation and pellets
were lysed. Supernatant and soluble lysate from pellet were analyzed by western blotting
and probed with a mouse monoclonal antibody against myc. (I) P: positive control (250ng
of Positope), lane 1: TM2-His (5X concentrated), lane 2: Chimera I (5X concentrated),
lane 3: Chimera II (20X concentrated) (II) P: positive control (250ng of Positope), lane 1:
TM2-His, lane 2: Chimera I, lane 3: Chimera II
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(A) Supernatant before purification

(B) Pellet lysate before purification

Figure 21. Western blotting analysis of chimeric proteins expressed in Pichia
Pastoris probed with anti-flag. Transformed Pichia strains were first grown in BMGY,
followed by BMMY. Supernatants were separated from via centrifugation and pellets
were lysed. Supernatant and soluble lysate from pellet were analyzed by western blotting
and probed with a mouse monoclonal antibody against flag. (I) P: positive control (50ng
of flag fusion protein), lane 1: TM2-His (5X concentrated), lane 2: EPCR-His (5X
concentrated), lane 3: Chimera I (5X concentrated), lane 4: Chimera II (20X
concentrated) (II) P: positive control (50ng of flag fusion protein), lane 1: TM2-His, lane
2: Chimera I, lane 3: Chimera I
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Figure 22 Western blotting analysis of His-resin purified chimeric proteins
expressed in Pichia Pastoris probed with anti-His. Transformed Pichia strains were
first grown in BMGY, followed by BMMY. Supernatants were separated from via
centrifugation and pellets were lysed. Supernatant and soluble lysate from pellet were
purified by His-resin and analyzed by western blotting and probed with a mouse
monoclonal antibody against histidine. (I) P: positive control (Positope), lane 1: TM2-His
from pellet, lane 2: Chimera II from pellet, lane 3: Chimera I from pellet, lane 4: EPCRHis from supernatant, lane 5: TM2-His from supernatant, lane 6: Chimera II from
supernatant, lane7: Chimera I from supernatant, lane 4: EPCR-His from supernatant.
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Figure 23. SDS-PAGE analysis of His-resin purified chimeric proteins expressed in
Pichia Pastoris with silver staining. Transformed Pichia strains were first grown in
BMGY, followed by BMMY. Supernatants were separated from via centrifugation and
pellets were lysed. Supernatant and soluble lysate from pellet were purified by His-resin
and analyzed by SDS-PAGE with silver staining. Lane1: TM2-His from pellet, lane 2:
Chimera II from pellet, lane 3: Chimera I from pellet, lane 4: EPCR-His from desalted
supernatant, lane 5: TM2-His from supernatant, lane 6: Chimera II from supernatant, lane
7: Chimera I from supernatant, lane 8: EPCR-His from desalted/lyophilized supernatant,
lane 9: EPCR-His from desalted supernatant.
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Figure 24. Western blotting analysis of His-resin purified chimeric proteins
expressed in Pichia pastoris to check the binding ability with human protein C.
Transformed Pichia strains were first grown in BMGY, followed by BMMY.
Supernatants were separated from via centrifugation and pellets were lysed. Supernatant
and soluble lysate from pellet were purified by His-resin and analyzed by western
blotting and incubated with 2ug/ml human protein C overnight at 4C. The signal was
detected with a HRP-conjugated sheep anti-human protein C. (I) P: positive control
(500ng human protein C), lane 1: TM2-His from pellet, lane 2: Chimera II from pellet,
lane 3: Chimera I from pellet, lane 4: EPCR-His from supernatant, lane 5: TM2-His from
supernatant, lane 6: Chimera I from supernatant, lane7: Chimera II from supernatant, lane
4: EPCR-His from supernatant.
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Figure 25. Western blotting analysis of His-resin purified chimeric proteins
expressed in Pichia pastoris to check the binding ability with human α thrombin.
Transformed Pichia strains were first grown in BMGY, followed by BMMY.
Supernatants were separated from via centrifugation and pellets were lysed. Supernatant
and soluble lysate from pellet were purified by His-resin and analyzed by western
blotting and incubated with 2ug/ml human α thrombin overnight at 4C. The signal was
detected with a HRP-conjugated sheep anti- human α thrombin. (I) P: positive control
(500ng human protein C), lane 1: TM2-His from pellet, lane 2: Chimera II from pellet,
lane 3: Chimera I from pellet, lane 4: EPCR-His from supernatant, lane 5: TM2-His from
supernatant, lane 6: Chimera I from supernatant, lane7: Chimera II from supernatant, lane
4: EPCR-His from supernatant.
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Figure 26. Solution phase Protein C activation assay of purified chimera I and
TM2-His from supernatant. Protein solutions ofTM2-His, chimera I, human α
thrombin, human Protein C, human activated Protein C, were prepared in reaction buffer.
For chimera I, 25 μl of reaction buffer, 25 μl of a 0.05 mg/ml hPC solution, and a various
concentration of partially pure chimera I from supernatant and pellet lysate were
incubated for 15 minutes at room temperature in a sterile 96 well cell culture plate. At
the same time, 25μl of reaction buffer and 25μl of a 0.05 mg/ml hPC solution were
incubated for 15 minutes at room temperature in the same cell culture plate, followed by
addition of 25 μl of various concentration of partially pure TM2-His from supernatant
and pellet lysate. Finally, 25 μl 0.03 μg/ml TR was added to the reaction mixture of
chimera I and TMs-His, which was incubated at 37˚C for 30 minutes. For the standard
curve of activated Protein C, 100 µl of various concentration of human activated Protein
C was added to the same 96 well cell culture plate. To measure the amount of activated
PC from each well, 25 μl of Spectrozyme aPC was added to a final concentration of
0.0004M. The reaction was incubated at 37˚C and the absorbance was taken after 0, 30
and 60 minute at 405 nm using a Beckman Coulter AD 340 UV/Vis microplate reader.
The concentration of generated APC was calculated using an APC in reaction buffer
calibration curve on the same cell culture plate.

58

Name of chimera

Composition & Size

Positive clones

chimera I

EPCR-myc-TM2-His6 (1395 bp)

#1, #4, #8

chimera II
EPCR-flag-2MT-His6 (1416 bp)
#2
Table 8. Sequence result of subcloned chimera I and chimera II with TOPO vector.
After amplification, gel-purified PCR products of chimera I and chimera II were
subcloned into TOPO vector. The DNA plasmids were transformed into chemically
competent cells of E. coli strain TOP-10. 10-50 µl from each transformation was spread
on a pre-warmed LB plates containing 50 µg/ml kanamycin and incubated overnight at
37°C. Ten positive clones of transformants from each chimera were selected and
transferred into 5ml of LB medium containing 50 µg/ml kanamycin to be cultured
overnight at 37°C. Then, plasmid DNA from each chimera was isolated and was
sequenced at University of Nebraska-Medical Center sequencing facility with gene
specific primers. Sequence analysis was performed using ChromasPro v1.5 software.

Name

Composition

Positive clones

chimera I

EPCR-myc-TM2-His6

#1-2, #1-4, #1-6, #1-7, #1-9

chimera II

EPCR-flag-2MT-His6

#2-1, #2-2, #2-3, #2-4, #2-6, #2-7, #2-8, #2-9

TM2-His
2MT-His6
#1, #2, #6, #10, #11, #13
Table 9. Cloning results of chimera I, chimera II, and TM2-His with pPICZ α A
vector. Clones from chimera I, chimera II, and TM2-His were digested by Xho I and Not
I for 3hours at 37˚C and then directionally ligated with pPICZ α A vector that was
digested with the same enzymes. The ligated plasmid was transformed into chemically
competent cells of E. coli strain TOP-10 according to manufacturer’s protocol. 50-100 µl
of each transformants were spread on a prewarmed LB plates containing 25 µg/ml Zeocin
and incubated overnight at 37°C. Ten positive clones from each transformant were
selected and transferred into 5ml of LB medium containing 25 µg/ml Zeocin to be
cultured overnight at 37°C. Then, plasmid DNA from each chimera was isolated and
sequenced at University of Nebraska-Medical Center sequencing facility with gene
specific primers. Sequence analysis was performed using ChromasPro v1.5 software.
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Pellet lysate
TM2‐His Chimera Chimera
I
II

TM2‐
His (5X)

Supernatant
Chimera I Chimera
(5X)
II (20X)

EPCR‐LL‐
His (5X)

anti‐His

+

+

+

+

+

+

+

anti‐EPCR

‐

+

+

‐

+

+

+

anti‐TM

+

+

+

+

+

+

‐

anti‐myc

‐

+

‐

‐

+

‐

‐

anti‐flag

‐

‐

+

‐

‐

+

‐

Table 10. Summary of Western blotting analysis with various antibodies to detect
the functional elements and the linkers of chimeric proteins
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Discussion
The goal of this study is to express genes encoding the functional elements of
EPCR and TM in an attempt to generate APC in-situ. The synthetic genes encoding
chimera I, chimera II, and TM2-His were successfully expressed in yeast Pichia host X33 strain. However, the expression and purification of these chimeric proteins need
improvement to enhance secretion of mature protein and obtain pure chimeric proteins of
chimera I, chimera II and TM2-His. When Pichia cells carrying the gene for chimera I
was grown up to 96 hours, the overexpression was observed on Western blotting analysis.
To resolve this issue, chimera I was grown up to 48 hours (Figure 11). Overall, the
expression level of all chimeric proteins from the pellet lysate was as high as that of
chimeric proteins from the supernatant, which indicated that the secretion of mature
protein into the medium was not sufficient. Secretion of mature protein is important since
it allows easy and efficient purification from the extracellular medium [84]. The purpose
of using pPICZ α A vector in this study is to secrete mature protein into the medium with
α-factor leader sequence. The partial secretion of chimeric proteins in this study might be
due to the ineffective signal cleavage at Kex2 cleavage site. To provide a hydrophilic
environment at Kex2 cleavage site, the addition of (Glu-Ala)2 is recommended, which
will be further removed by Ste 13 dipeptidyl aminopeptidase [85, 86]. Brake et al.
suggested that the repeating residue of (Glu-Ala) was not necessary for a proper
processing of fusion protein hEGF, but the presence of repeating sequence of (Glu-Ala)
might prevent the accumulation of intracellular active α-factor and be essential for the
correct folding of fusion between α-factor leader and foreign proteins.
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Along with the partial secretion of chimeric proteins, proteolytic degradation of
secreted chimeric proteins has been observed in Figure 17/18/19/20/21. All crude
chimeric proteins from the supernatant have multiple small fragments with a strong band
at their expected molecular weight. These small fragments are caused by the inactivation
of protease inhibitors in an aqueous reaction environment over a 48 hour period [87] even
though 2 mM of PMSF (Phenylmethanesulphonyfluoride, protease inhibitor) in 100%
methanol has been added to the cell culture at the first 12 hour induction. A large amount
of oxygen consumption for methanol induction and additional methanol feeding every 12
hours contribute to the accumulation of hydrogen peroxide as a by-product inside the cell,
which can cause oxidative stress on the cell to bring out more protease activity. Sinha et
al. reported that proteolytic activity was observed when the carbon source switched from
glycerol to methanol and reached a maximum between 60 to 72 hours induction time
[88]. In this sense, the lower molecular weight fragments of chimera I protein and
chimera II proteins are suspected to be a truncated form of chimeric proteins caused by
the proteolytic activity. Both chimera I protein and chimera II protein show a strong band
at the expected molecular weight of 78 kDa with another strong band at 40 kDa. Li et al.
have observed the similar phenomena in the attempt of producing 58 and 75 kDa fusion
proteins, MBP-FXa-cargo-mcy-His6 [89]. All these proteins had a band at 45 kDa
corresponding molecular weight of MBP, and Li et al. suggested that the proteolysis
occurred at or close to FXa or in the C-terminal MBP region. For chimera I protein and
chimera II protein, the proteolysis occurred in the C-terminal EPCR region since both
these proteins were detected with anti-His, anti-EPCR, ant-His, and anti-myc/anti-flag.
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To reduce the photolytic degradation of secreted proteins, it is important to explore the
choice of protease inhibitor with reduced induction times on methanol.
Another interesting fact is that the expression level of Pichia cells carrying the
genes for chimera I, and chimera II, and TM2-His was different from each other (Figure
14/15/16). The expression of Pichia cells carrying the gene for TM2-His was more
successful than others while the expression of Pichia cells carrying the gene for chimera
II was poor. This might be due to the composition of each chimeric protein. A chimeric
protein TM2-His contains a partial gene sequence (EGF 4/5/6) of the whole
thrombomodulin molecule, so the expression is much easier than the expression of
bifunctional proteins such as chimera I and chimera II. Protein chimera I and protein
chimera II contain both EPCR (binding of Protein C and activated Protein C) and TM
(binding of thrombin). The expression of Pichia cells carrying the gene for chimera II is
even worse than that of chimera I. This might be explained by the reversed amino acid
sequence of thrombomodulin in chimera II since other elements of both genes are
identical except for the linker protein and the order of amino acid sequence for TM. The
reversed amino acid sequence of TM is not natural and it might affect the stability of the
protein construction. Another important domain in chimeric protein is an appropriate
linker peptide for the multi-functional protein to work independently by keeping the
spatial separation of the multi-functional domains [65]. Aral et al. introduced α-helical
linker, (EAAAK)n to separate two green fluorescent protein (GFP) variants and
demonstrated a good separation of the functional domains and kept them independent,
without disturbing domains. The linker peptide used for chimera I and chimera II is a
myc epitope and a flag epitope, respectively. These linker peptides are flexible but they
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do not provide much space between EPCR and TM, so it might affect the biological
function of the chimeric proteins. All these factors can contribute to the expression of
chimeric proteins.
Prior to testing the biological activity of the chimeric proteins to activate Protein
C, His-resin affinity purification is used for a single step purification of protein
containing His-tag sequence by metal chelation chromatography. His-tag sequence binds
to Ni2+ ion immobilized on His-bind resin in a batch mode and the results are shown in
Figure 21 and Figure 22. The final products of the chimeric proteins are partially pure
since every sample with silver staining has a mysterious band at 62 kDa. Especially, the
result of EPCR-His protein purification is not agreeable with the literature reported
previously [90]. Mamedov et al. purified the same EPCR-His protein with His-resin
affinity column purification and the final product showed only one protein band at 38
kDa. These results suggest that the efficiency of column purification is better than batch
mode purification since the batch mode has a limitation in complete removal of residues
from each step, especially after binding and washing steps. This is probably why the
final protein products after purification have a protein band at 62 kDa. In addition,
purified protein from the supernatant of chimera II was not detected on both Western blot
and silver staining. This could be the result of inappropriately handling protein samples
along with a low expression level. After the purification, the protein sample prepared for
Western blot analysis showed a sign of pH problem by turn into yellow instead of
purplish blue. The sample was too acidic to run on the gel with the running buffer at 7.0,
which led to an aggregation of protein sample in the gel well. This could be fixed by a
series of dialysis immediately after purification to remove a residual imidazole from
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elution buffer. Proteins purified from the pellet lysates show numerous protein bands on
silver staining, which is occurred by a combination of a strong proteolytic activity inside
the cell and degradation of protein due to inadequate protease inhibitor use. The cell lysis
buffer used in this study contains protease inhibitors, 1 mM of EDTA and 2 mM of
PMSF, but the combination of EDTA and PMSF is not sufficient to prevent the
degradation of protein. More options for protease inhibitors need to be explored and
shorten induction times to reduce the amount of vacuolar proteases and hydrogen
peroxide accumulation inside the cell. In spite of all the issues, the biological activity of
the final protein products was tested.
Solution phase assay was conducted to demonstrate that chimera I protein and
TM2-His protein were biologically active to catalyze activation of Protein C (Figure 26).
Chimera I protein and TM2-His protein activated the Protein C; however, the activity of
these two proteins is much less than that of control with commercial proteins of hPC,
rabbit lung TM, and thrombin in the absence of EPCR. The activity of control is ~80-fold
higher than chimera I protein from pellet lysate and ~910-fold higher than chimera I
protein from supernatant. The activity of control is ~180-fold higher than TM2-His
protein from pellet lysate and ~1600-fold higher than TM2-His protein from supernatant.
In addition, the activity of proteins from pellet lysate generated more APC than proteins
from supernatant. It is possible that the protein from pellet lysate still remain the α-factor
signal sequence so it might alter the protein folding process inside the cell, which might
affect the function of protein. Nonetheless, the overall activity of chimera I protein is
almost 2-fold higher than that of TM2-His protein. The activity ratio of chimera I and
TM2-His is 1.8 at 961 nM (supernatant), 1.84 at 320 nM (pellet), and 2.0 at 160 nM
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(pellet). This can be explained by the unique molecular composition of chimera I (EPCRflag-2MT-His6). While thrombomodulin in TM2-His protein activates Protein C only by
forming a complex with a thrombin, EPCR in chimera I protein stimulates Protein C
activation mediated by the thrombin/thrombomodulin complex [37]. The Gla-domain of
PC/APC interacts with EPCR [33], and the Gla-domain of PC also interacts with TM
and/or TR[49]. The result of PC activation assay proves our hypothesis that
incorporating EPCR with TM in the chimeric protein can stimulate the activation of
Protein C better than TM alone.
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Conclusion
The synthetic genes encoding chimera I, chimera II, and TM2-His have been
successfully expressed in the yeast, Pichia pastoris X-33 strain. Overall, expression level
of chimera I, chimera II, and TM2-His is low, and mature proteins are partially secreted
into the medium, and the final products of purified proteins were partially pure. In spite
of all these issues, this study demonstrates that chimera I protein and TM2-His protein
remain the biological activity to activate Protein C from the solution phase experiment.
Further, this study has shown that the activity of chimera I is almost twice higher than
that of TM2-His by co-expressing EPCR and TM in the chimera I protein.
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Future Work
This study demonstrates the expression of genes encoding functional elements of
EPCR and TM in an attempt to generate APC in-situ and the biological activity of
chimera I protein to activate Protein C. However, several issues need to be resolved to
improve the production of chimeric proteins. To optimize the secretion of target protein,
the addition of repeated sequence of (Glu-Ala) after Kex2 cleavage site needs to be
considered in the design of DNA sequence. To improve the function of multi-functional
protein, the use of a helical linker between EPCR and TM might be a better choice by
keeping the spatial separation of the multi-functional domains. To reduce or prevent the
degradation of protein, the use of protease inhibitor cocktail is recommended for the
induction and process of protein at any stage, which will affect the quality of final protein
product. Once chimera I and chimera II are successfully expressed and purified, these
proteins can be coated onto the surface of the biomaterial surfaces to delay the blood clot.
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Appendices
1. Chimera I Design
a t c t c g a g a a a a g a FCSQDASDGLQRLHMLQISYFRDPYH
VWYQGNASLGGHLTHVLEGPDTNTTIIQLQPLQEPESW
ARTQSGLQSYLLQFHGLVRLVHQERTLAFPLTIRCFLG
CELPPEGSRAHVFFEVAVNGSSFVSFRPERALWQADTQ
VTSGVVTFTLQQLNAYNRTRYELREFLEDTCVQYVQK
HISAENTKGSQTSRSYTSEQKLISEEDLNSAVDCSVENG
GCEHACNAIPGAPRCQCPAGAALQADGRSCTASATQSC
N D L C E H F C V P N P D Q P G S Y S C Met C E T G Y R L A A D Q H R C E
DVDDCILEPSPCPQRCVNTQGGFECHCYPNYDLVDGEC
VEPVDPCFRANCEYQCQPLNQTSYLCVCAEGFAPIPHE
P H R C Q Met F C N Q T A C P A D C D P N T Q A S C E C P E G Y I L D D G F
ICTDIDECENGGFCSGVCHNLPGTFECICGPDSALVRHI
G T D C D S G K H H H H H H Stop g c g g c c g c t a

Lower-case: nucleotides

Upper Case: Amino Acids

Black- added sequence

Red- EPCR mature peptide

Green- Flag epitope

Blue- TM-2 (Asp226 to Lys466) normal

Orange- His 6 tag

Underline-Xho1 and Not1 sites
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2. Chimera I Starting original nucleotide sequence

ATCTCGAGAAAAGATTTTGTAGTCAAGATGCTTCTGATGGTCTACAAAGATTG
CATATGTTGCAAATCTCTTACTTTCGTGATCCTTATCATGTTTGGTACCAAGGT
AATGCTTCTTTGGGTGGACATTTGACTCATGTTTTGGAAGGTCCAGATACTAA
TACTACTATCATTCAATTGCAACCTTTGCAAGAACCTGAAAGTTGGGCTCGTA
CTCAAAGTGGTTTGCAATCTTACTTGTTACAATTTCATGGTCTAGTTCGTTTGG
TTCATCAAGAACGTACTTTGGCTTTTCCTTTGACTATCCGTTGTTTTTTGGGTT
GTGAATTGCCTCCTGAAGGTTCTAGAGCTCATGTTTTTTTTGAAGTTGCTGTTA
ATGGTAGTTCTTTTGTTAGTTTTCGTCCAGAAAGAGCTTTGTGGCAAGCTGAT
ACTCAAGTCACCTCTGGAGTTGTCACCTTTACCTTGCAACAATTGAATGCTTA
CAATCGTACTCGTTATGAATTACGTGAATTTCTTGAAGATACTTGTGTTCAAT
ATGTTCAAAAACATATTTCTGCTGAAAATACTAAAGGTAGTCAAACTAGTCG
TTCTTACACTTCTGAACAAAAACTCATCTCAGAAGAGGATCTGAATAGCGCC
GTCGACTGTTCTGTTGAAAATGGTGGTTGTGAACATGCTTGTAATGCTATTCC
AGGTGCTCCAAGATGTCAATGTCCAGCTGGTGCTGCTTTGCAAGCTGATGGTA
GATCTTGTACTGCTTCTGCTACTCAATCTTGTAATGATTTGTGTGAACATTTCT
GTGTTCCAAATCCAGATCAACCAGGTTCTTATTCTTGTATGTGTGAAACTGGT
TATAGATTGGCTGCTGATCAACATAGATGTGAAGATGTTGATGATTGTATTTT
GGAACCATCTCCATGTCCACAAAGATGTGTTAATACTCAAGGTGGTTTCGAAT
GTCATTGTTATCCAAATTATGATTTGGTTGATGGTGAATGTGTTGAACCAGTT
GATCCATGTTTCAGAGCTAATTGTGAATATCAATGTCAACCATTGAATCAAAC
TTCTTATTTGTGTGTTTGTGCTGAAGGTTTCGCTCCAATTCCACATGAACCACA
TAGATGTCAAATGTTCTGTAATCAAACTGCTTGTCCAGCTGATTGTGATCCAA
ATACTCAAGCTTCTTGTGAATGTCCAGAAGGTTATATTTTGGATGATGGTTTC
ATTTGTACTGATATTGATGAATGTGAAAATGGTGGTTTCTGTTCTGGTGTTTG
TCATAATTTGCCAGGTACTTTCGAATGTATTTGTGGTCCAGATTCTGCTTTGGT
TAGACATATTGGTACTGATTGTGATTCTGGTAAGCATCATCACCATCACCACT
AAGCGGCCGCTA
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3. Chimera II Design

atctcgagaaaagaFCSQDASDGLQRLHMLQISYFRDPY
HVWYQGNASLGGHLTHVLEGPDTNTTIIQLQPLQEP
ESWARTQSGLQSYLLQFHGLVRLVHQERTLAFPLTI
RCFLGCELPPEGSRAHVFFEVAVNGSSFVSFRPERAL
WQADTQVTSGVVTFTLQQLNAYNRTRYELREFLED
TCVQYVQKHISAENTKGSQTSRSYTSKKRKKDYKD
DDDKKRKRKCDTGIHRVLASDPGCICEFTGPLNHCV
GSCFGGNECEDIDTCIFGDDLIYGEPCECSAQTNPDC
DAPCATQNCFMQCRHPEHPIPAFGEACVCLYSTQNL
PQCQYECNARFCPDVPEVCEGDVLDYNPYCHCEFG
GQTNVCRQPCPSPELICDDVDECRHQDAALRYGTEC
MCSYSGPQDPNPVCFHECLDNCSQTASATCSRGDAQ
LAAGAPCQCRPAGPIANCAHECGGNEVSCDWARKK
K R H H H H H H Stop g c g g c c g c t a

Lower-case: nucleotides

Upper Case: Amino Acids

Black- added sequence

Red- EPCR mature peptide

Green- Flag epitope

Blue- TM-2 (Ala224 to Cys462) flipped

Orange- His 6 tag

Underline-Xho1 and Not1 sites
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4. Chimera II Starting original nucleotide sequence

ATCTCGAGAAAAGATTCTGCTCTCAAGATGCTTCTGATGGATTGCAAAGATTG
CATATGTTGCAAATTTCTTACTTCAGAGATCCTTACCACGTTTGGTACCAGGG
TAACGCTTCTTTGGGTGGACATTTGACTCACGTTTTGGAGGGTCCTGATACTA
ACACTACTATCATTCAATTGCAACCTTTGCAGGAACCTGAATCTTGGGCCAGA
ACCCAATCTGGATTGCAGTCTTACTTGTTGCAGTTTCATGGTTTGGTTAGATT
GGTTCACCAGGAGAGAACTTTGGCCTTTCCTTTGACCATTAGATGTTTCTTGG
GATGTGAATTGCCTCCAGAAGGTTCTAGAGCTCATGTTTTTTTCGAAGTTGCT
GTTAACGGTTCTTCTTTCGTTTCTTTCAGACCTGAGAGAGCCTTGTGGCAGGC
TGATACTCAGGTTACCTCTGGAGTTGTTACTTTCACCTTGCAACAGTTGAACG
CTTATAACAGAACCAGATATGAATTGAGAGAATTCTTGGAAGATACTTGTGT
TCAGTATGTTCAAAAGCACATTTCTGCCGAAAACACCAAGGGTTCTCAAACTT
CTAGATCTTACACCTCTAAGAAAAGAAAGAAGGATTACAAAGACGACGACG
ATAAGAAGAGAAAGAGAAAATGTGACACTGGTATCCACAGAGTTTTGGCTTC
TGACCCTGGATGCATTTGTGAGTTTACTGGACCTTTGAACCACTGTGTTGGTT
CTTGTTTTGGTGGTAACGAGTGTGAGGACATTGACACTTGCATTTTTGGAGAC
GATTTGATTTATGGTGAGCCATGCGAATGTTCTGCCCAAACTAACCCTGATTG
CGACGCCCCATGTGCCACTCAAAACTGTTTCATGCAGTGTAGACACCCTGAA
CATCCTATTCCAGCTTTCGGTGAAGCTTGCGTTTGTTTGTATTCTACTCAGAAC
TTGCCACAGTGCCAGTACGAGTGTAACGCTAGATTTTGCCCTGACGTTCCTGA
AGTTTGTGAGGGTGATGTTTTGGACTACAACCCATACTGTCATTGCGAATTCG
GTGGACAGACTAACGTTTGCAGACAACCTTGCCCTTCTCCAGAATTGATCTGT
GATGACGTTGATGAATGCAGACACCAGGATGCCGCCTTGAGATATGGAACCG
AATGTATGTGTTCTTATTCTGGTCCTCAAGATCCTAACCCAGTTTGTTTCCATG
AGTGCTTGGACAATTGTTCTCAGACCGCTTCTGCCACCTGTTCTAGAGGAGAT
GCCCAGTTGGCTGCTGGTGCTCCTTGCCAATGTAGACCTGCTGGTCCAATTGC
TAACTGTGCTCACGAATGTGGAGGTAATGAGGTTTCTTGTGACTGGGCTAGA
AAGAAGAAGAGACATCATCACCATCACCACTAAGCGGCCGCTA
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5. TM2-His Design
ATCTCGAGAAAAGA A W D C S V E N G G C E H A C N A I P G A P R C Q C P A
GAALQADGRSCTASATQSCNDLCEHFCVPNPDQPGSYSC
MCETGYRLAADQHRCEDVDDCILEPSPCPQRCVNTQGGF
ECHCYPNYDLVDGECVEPVDPCFRANCEYQCQPLNQTSY
LCVCAEGFAPIPHEPHRCQMFCNQTACPADCDPNTQASC
ECPEGYILDDGFICTDIDECENGGFCSGVCHNLPGTFECIC
G P D S A L V R H I G T D C CATCATCACCATCACCACTAAGCGGCCGCTA
Blue-TM-2 (Ala224 to Cys462)
Underline-Xho I and Not I sites
Orange-His 6 tag DNA sequence

6. Chimera II Starting original nucleotide sequence
ATCTC-GAG, AAA, AGA
GCTTGGGATTGCTCTGTCGAAAATGGAGGTTGTGAACATGCTTGTAATGCCAT
CCCAGGTGCCCCAAGATGCCAGTGTCCAGCAGGAGCTGCCTTGCAAGCTGAT
GGTAGATCTTGTACCGCATCTGCAACTCAGTCCTGTAATGATTTGTGCGAGCA
CTTCTGTGTTCCTAACCCAGATCAACCTGGATCCTACTCTTGTATGTGTGAGA
CAGGTTACAGATTGGCTGCTGATCAACATAGATGTGAAGATGTTGACGACTG
TATTTTGGAACCTTCTCCATGTCCACAAAGATGTGTCAACACTCAAGGTGGTT
TTGAGTGTCATTGCTATCCAAATTACGATTTGGTTGATGGAGAGTGCGTCGAA
CCAGTTGACCCATGTTTCAGAGCTAATTGTGAGTACCAGTGCCAGCCATTGAA
TCAAACTTCCTATTTGTGTGTCTGCGCCGAAGGTTTTGCCCCAATCCCTCATG
AACCTCACAGATGTCAGATGTTTTGTAATCAGACTGCCTGTCCAGCCGACTGC
GACCCAAATACTCAGGCCTCCTGTGAATGTCCAGAAGGATACATTTTGGATG
ATGGTTTTATTTGTACAGACATTGATGAGTGTGAAAACGGTGGATTTTGTTCC
GGTGTCTGTCACAACTTGCCTGGTACTTTCGAATGCATTTGCGGACCTGATTC
CGCTTTGGTCAGACACATCGGAACTGACTGT
CAT, CAT, CAC, CAT, CAC, CAC, TAA, GCG-GCCGCTA

